1
|
Liu JP, Shen KY, Cheng WC, Chang WC, Hsieh CY, Lo CC, Kuo TT, Lin CC, Liu SJ, Huang WC, Sher YP. ADAM9 drives the immunosuppressive microenvironment by cholesterol biosynthesis-mediated activation of IL6-STAT3 signaling for lung tumor progression. Am J Cancer Res 2024; 14:1850-1865. [PMID: 38726266 PMCID: PMC11076253 DOI: 10.62347/lodv2387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2024] [Accepted: 04/07/2024] [Indexed: 05/12/2024] Open
Abstract
Chronic inflammation associated with lung cancers contributes to immunosuppressive tumor microenvironments, reducing CD8+ T-cell function and leading to poor patient outcomes. A disintegrin and metalloprotease domain 9 (ADAM9) promotes cancer progression. Here, we aim to elucidate the role of ADAM9 in the immunosuppressive tumor microenvironment. A bioinformatic analysis of TIMER2.0 was used to investigate the correlation of ADAM9 and to infiltrate immune cells in the human lung cancer database and mouse lung tumor samples. Flow cytometry, immunohistochemistry, and RNA sequencing (RNA-seq) were performed to investigate the ADAM9-mediated immunosuppressive microenvironment. The coculture system of lung cancer cells with immune cells, cytokine array assays, and proteomic approach was used to investigate the mechanism. By analyzing the human LUAD database and the mouse lung cancer models, we showed that ADAM9 was associated with the immunosuppressive microenvironment. Additionally, ADAM9 released IL6 protein from cancer cells to inhibit IL12p40 secretion from dendritic cells, therefore leading to dendritic cell dysfunction and further affecting T-cell functions. Proteomic analysis indicated that ADAM9 promoted cholesterol biosynthesis and increased IL6-STAT3 signaling. Mechanistically, ADAM9 reduced the protein stability of LDLR, resulting in reduced cholesterol uptake and induced cholesterol biosynthesis. Moreover, LDLR reduction enhanced IL6-STAT3 activation. We reveal that ADAM9 has a novel biological function that drives the immunosuppressive tumor microenvironment by linking lung cancer's metabolic and signaling axes. Thus, by targeting ADAM9 an innovative and promising therapeutic opportunity was indicated for regulating the immunosuppression of lung cancer.
Collapse
Affiliation(s)
- Jing-Pei Liu
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
| | - Kuan-Yin Shen
- School of Dentistry, Tri-Service General Hospital and National Defense Medical CenterTaipei 114, Taiwan
| | - Wei-Chung Cheng
- The Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia SinicaTaichung 404, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University HospitalTaichung 404, Taiwan
| | - Chih-Ying Hsieh
- Division of Hematology and Oncology, China Medical University HospitalTaichung 404, Taiwan
| | - Chia-Chien Lo
- Center for Molecular Medicine, China Medical University HospitalTaichung 404, Taiwan
| | - Ting-Ting Kuo
- Institute of Biochemistry and Molecular Biology, China Medical UniversityTaichung 404, Taiwan
| | - Ching-Chan Lin
- Division of Hematology and Oncology, China Medical University HospitalTaichung 404, Taiwan
| | - Shih-Jen Liu
- National Institute of Infectious Diseases and Vaccinology, National Health Research InstitutesMiaoli 350, Taiwan
| | - Wen-Chin Huang
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
- Graduate Institute of Cell Biology, China Medical UniversityTaichung 404, Taiwan
- The International Master’s Program of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
| | - Yuh-Pyng Sher
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
- The Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia SinicaTaichung 404, Taiwan
- Center for Molecular Medicine, China Medical University HospitalTaichung 404, Taiwan
- Institute of Biochemistry and Molecular Biology, China Medical UniversityTaichung 404, Taiwan
- The International Master’s Program of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
- Cancer Biology and Precision Therapeutics Center, China Medical UniversityTaichung 404, Taiwan
| |
Collapse
|
2
|
Wu CS, Li YC, Peng SL, Chen CY, Chen HF, Hsueh PR, Wang WJ, Liu YY, Jiang CL, Chang WC, Wang SC, Hung MC. Coffee as a dietary strategy to prevent SARS-CoV-2 infection. Cell Biosci 2023; 13:210. [PMID: 37964389 PMCID: PMC10644613 DOI: 10.1186/s13578-023-01154-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Accepted: 10/25/2023] [Indexed: 11/16/2023] Open
Abstract
BACKGROUND To date, most countries lifted the restriction requirement and coexisted with SARS-CoV-2. Thus, dietary behavior for preventing SARS-CoV-2 infection becomes an interesting issue on a daily basis. Coffee consumption is connected with reduced COVID-19 risk and correlated to COVID-19 severity. However, the mechanisms of coffee for the reduction of COVID-19 risk are still unclear. RESULTS Here, we identified that coffee can inhibit multiple variants of the SARS-CoV-2 infection by restraining the binding of the SARS-CoV-2 spike protein to human angiotensin-converting enzyme 2 (ACE2), and reducing transmembrane serine protease 2 (TMPRSS2) and cathepsin L (CTSL) activity. Then, we used the method of "Here" (HRMS-exploring-recombination-examining) and found that isochlorogenic acid A, B, and C of coffee ingredients showed their potential to inhibit SARS-CoV-2 infection (inhibitory efficiency 43-54%). In addition, decaffeinated coffee still preserves inhibitory activity against SARS-CoV-2. Finally, in a human trial of 64 subjects, we identified that coffee consumption (approximately 1-2 cups/day) is sufficient to inhibit infection of multiple variants of SARS-CoV-2 entry, suggesting coffee could be a dietary strategy to prevent SARS-CoV2 infection. CONCLUSIONS This study verified moderate coffee consumption, including decaffeination, can provide a new guideline for the prevention of SARS-CoV-2. Based on the results, we also suggest a coffee-drinking plan for people to prevent infection in the post-COVID-19 era.
Collapse
Affiliation(s)
- Chen-Shiou Wu
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan
| | - Yi-Chuan Li
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
| | - Shin-Lei Peng
- Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung, Taiwan
- Neuroscience and Brain Disease Center, China Medical University, Taichung, Taiwan
| | - Chung-Yu Chen
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan
| | - Hsiao-Fan Chen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan
| | - Po-Ren Hsueh
- Departments of Laboratory Medicine and Internal Medicine, School of Medicine, China Medical University Hospital, China Medical University Taichung, Taichung, Taiwan
| | - Wei-Jan Wang
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
| | - Yen-Yi Liu
- Department of Biology, National Changhua University of Education, Changhua, Taiwan
| | - Ciao-Ling Jiang
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
| | - Shao-Chun Wang
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
- Department of Biotechnology, Asia University, Taichung, Taiwan
- Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung, Taiwan
| | - Mien-Chie Hung
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
- Department of Biotechnology, Asia University, Taichung, Taiwan.
- Cancer Biology and Precision Therapeutics Center, China Medical University, Taichung, Taiwan.
- Institute of Biochemistry and Molecular Biology, China Medical University, Taichung, Taiwan.
| |
Collapse
|
3
|
Hsieh CY, Lin CC, Chang WC. Taxanes in the Treatment of Head and Neck Squamous Cell Carcinoma. Biomedicines 2023; 11:2887. [PMID: 38001888 PMCID: PMC10669519 DOI: 10.3390/biomedicines11112887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 10/22/2023] [Accepted: 10/24/2023] [Indexed: 11/26/2023] Open
Abstract
Taxanes, particularly docetaxel (DTX), has been widely used for combination therapy of head and neck squamous cell carcinoma (HNSCC). For locally advanced unresectable HNSCC, DTX combined with cisplatin and 5-fluorouracil as a revolutionary treatment revealed an advantage in the improvement of patient outcome. In addition, DTX plus immune check inhibitors (ICIs) showed low toxicity and an increased response of patients with recurrent or metastatic HNSCC (R/M HNSCC). Accumulated data indicate that taxanes not only function as antimitotics but also impair diverse oncogenic signalings, including angiogenesis, inflammatory response, ROS production, and apoptosis induction. However, despite an initial response, the development of resistance remains a major obstacle to treatment response. Taxane resistance could result from intrinsic mechanisms, such as enhanced DNA/RNA damage repair, increased drug efflux, and apoptosis inhibition, and extrinsic effects, such as angiogenesis and interactions between tumor cells and immune cells. This review provides an overview of taxanes therapy applied in different stages of HNSCC and describe the mechanisms of taxane resistance in HNSCC. Through a detailed understanding, the mechanisms of resistance may help in developing the potential therapeutic methods and the effective combination strategies to overcome drug resistance.
Collapse
Affiliation(s)
- Ching-Yun Hsieh
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan;
| | - Ching-Chan Lin
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan;
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung 40402, Taiwan
| |
Collapse
|
4
|
Chen HF, Wang WJ, Chen CY, Chang WC, Hsueh PR, Peng SL, Wu CS, Chen Y, Huang HY, Shen WJ, Wang SC, Hung MC. The natural tannins oligomeric proanthocyanidins and punicalagin are potent inhibitors of infection by SARS-CoV-2. eLife 2023; 12:e84899. [PMID: 37642993 PMCID: PMC10465125 DOI: 10.7554/elife.84899] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 07/17/2023] [Indexed: 08/31/2023] Open
Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic continues to infect people worldwide. While the vaccinated population has been increasing, the rising breakthrough infection persists in the vaccinated population. For living with the virus, the dietary guidelines to prevent virus infection are worthy of and timely to develop further. Tannic acid has been demonstrated to be an effective inhibitor of coronavirus and is under clinical trial. Here we found that two other members of the tannins family, oligomeric proanthocyanidins (OPCs) and punicalagin, are also potent inhibitors against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with different mechanisms. OPCs and punicalagin showed inhibitory activity against omicron variants of SARS-CoV-2 infection. The water extractant of the grape seed was rich in OPCs and also exhibited the strongest inhibitory activities for viral entry of wild-type and other variants in vitro. Moreover, we evaluated the inhibitory activity of grape seed extractants (GSE) supplementation against SARS-CoV-2 viral entry in vivo and observed that serum samples from the healthy human subjects had suppressive activity against different variants of SARS-CoV-2 Vpp infection after taking GSE capsules. Our results suggest that natural tannins acted as potent inhibitors against SARS-CoV-2 infection, and GSE supplementation could serve as healthy food for infection prevention.
Collapse
Affiliation(s)
- Hsiao-Fan Chen
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichungTaiwan
- Research Center for Cancer Biology, China Medical UniversityTaichungTaiwan
| | - Wei-Jan Wang
- Research Center for Cancer Biology, China Medical UniversityTaichungTaiwan
- Department of Biological Science and Technology, College of Life Sciences, China Medical UniversityTaichungTaiwan
| | - Chung-Yu Chen
- Research Center for Cancer Biology, China Medical UniversityTaichungTaiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical UniversityTaichungTaiwan
| | - Po-Ren Hsueh
- Departments of Laboratory Medicine and Internal Medicine, China Medical University Hospital, School of Medicine, China Medical UniversityTaichungTaiwan
| | - Shin-Lei Peng
- Department of Biomedical Imaging and Radiological Science, China Medical UniversityTaichungTaiwan
- Neuroscience and Brain Disease Center, China Medical UniversityTaichungTaiwan
| | - Chen-Shiou Wu
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichungTaiwan
- Research Center for Cancer Biology, China Medical UniversityTaichungTaiwan
| | - Yeh Chen
- Department of Biological Science and Technology, College of Life Sciences, China Medical UniversityTaichungTaiwan
- Institute of New Drug Development, China Medical UniversityTaichungTaiwan
| | - Hsin-Yu Huang
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichungTaiwan
| | - Wan-Jou Shen
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichungTaiwan
| | - Shao-Chun Wang
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichungTaiwan
- Research Center for Cancer Biology, China Medical UniversityTaichungTaiwan
- Center for Molecular Medicine, China Medical University Hospital, China Medical UniversityTaichungTaiwan
- Cancer Biology and Precision Therapeutics Center, China Medical UniversityTaichungTaiwan
- Department of Biotechnology, Asia UniversityTaichungTaiwan
| | - Mien-Chie Hung
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichungTaiwan
- Research Center for Cancer Biology, China Medical UniversityTaichungTaiwan
- Center for Molecular Medicine, China Medical University Hospital, China Medical UniversityTaichungTaiwan
- Cancer Biology and Precision Therapeutics Center, China Medical UniversityTaichungTaiwan
- Department of Biotechnology, Asia UniversityTaichungTaiwan
- Institute of Biochemistry and Molecular Biology, China Medical UniversityTaichungTaiwan
| |
Collapse
|
5
|
Wang HC, Chang WC, Lee DY, Li XG, Hung MC. IRG1/Itaconate induces metabolic reprogramming to suppress ER-positive breast cancer cell growth. Am J Cancer Res 2023; 13:1067-1081. [PMID: 37034222 PMCID: PMC10077032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Accepted: 03/01/2023] [Indexed: 04/11/2023] Open
Abstract
Most breast cancers are estrogen receptor (ER)-positive, targeted by endocrine therapies, but chemoresistance remains a significant challenge in treating the disease. Altered intracellular metabolite has closely connected with the pathogenic process of breast cancer and drug resistance. Itaconate is an anti-inflammatory metabolite generated from converting cis-aconitate in the tricarboxylic acid (TCA) cycle by the immune response gene 1 (IRG1). However, the potential role of IRG1/Itaconate in the crosstalk of metabolic pathways and tumor development is currently unknown. We tested the hypothesis that IRG1/Itaconate controls metabolic homeostasis to modulate breast cancer cell growth. We showed that breast cancers harboring an IRG1 deletion displayed a worse prognosis than those without IRG1 deletion; approximately 70% of breast cancer with IRG1 deletion were ER-positive. There was no significant difference in the IRG1 copy number, mRNA, and protein levels between ER-positive and ER-negative breast cancer cell lines and breast tumors. Itaconate selectively inhibited ER-positive breast cancer cell growth via the blockade of DNA synthesis and the induction of apoptosis. Mechanistically, IRG1 overexpression led to decreased intermediate levels of glycolysis, the TCA cycle, and lipid metabolism to compromise the entire biomass and energy of the cell. Itaconate inhibited the enzymatic activity of succinate dehydrogenase (SDH) in the mitochondrial electron-transport chain, concomitant with reactive oxygen species (ROS) production and the decreased adenylate kinase (AK) activities, which, in turn, induced AMP-activated protein kinase (AMPK) activation to restore metabolic homeostasis. These results suggest a new regulatory pathway whereby IRG1/Itaconate controls metabolic homeostasis in ER-positive breast cancer cells, which may contribute to developing more efficacious therapeutic strategies for breast cancer.
Collapse
Affiliation(s)
- Hsueh-Chun Wang
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 406040, Taiwan
- Research Center for Cancer Biology, China Medical UniversityTaichung 406040, Taiwan
| | - Wei-Chao Chang
- Research Center for Cancer Biology, China Medical UniversityTaichung 406040, Taiwan
- Center for Molecular Medicine, China Medical University Hospital, China Medical UniversityTaichung 406040, Taiwan
| | - Der-Yen Lee
- Graduate Institute of Integrated Medicine, China Medical UniversityTaichung 406040, Taiwan
| | - Xing-Guo Li
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 406040, Taiwan
- Research Center for Cancer Biology, China Medical UniversityTaichung 406040, Taiwan
- Institute of Biochemistry and Molecular Biology, China Medical UniversityTaichung 406040, Taiwan
| | - Mien-Chie Hung
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 406040, Taiwan
- Institute of Biochemistry and Molecular Biology, China Medical UniversityTaichung 406040, Taiwan
| |
Collapse
|
6
|
Hsieh CY, Lin CC, Huang YW, Chen JH, Tsou YA, Chang LC, Fan CC, Lin CY, Chang WC. Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signaling. JCI Insight 2022; 7:157285. [PMID: 36264639 PMCID: PMC9746909 DOI: 10.1172/jci.insight.157285] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2021] [Accepted: 10/18/2022] [Indexed: 01/12/2023] Open
Abstract
Docetaxel (DTX) combined with cisplatin and 5-fluorouracil has been used as induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). However, the development of acquired resistance remains a major obstacle to treatment response. Tumor-associated macrophages are associated with chemotherapeutic resistance. In the present study, increased infiltration of macrophages into the tumor microenvironment (TME) was significantly associated with shorter overall survival and increased resistance to chemotherapeutic drugs, particularly DTX, in patients with HNSCC. Macrophage coculture induced expression of intercellular adhesion molecule 1 (ICAM1), which promotes stemness and the formation of polyploid giant cancer cells, thereby reducing the efficacy of DTX. Both genetic silencing and pharmacological inhibition of ICAM1 sensitized HNSCC to DTX. Macrophage secretion of IL-1β was found to induce tumor expression of ICAM1. IL-1β neutralization and IL-1 receptor blockade reversed DTX resistance induced by macrophage coculture. IL-1β activated superoxide dismutase 2 and inhibited catalase, thereby modulating intracellular levels of ROS and inducing ICAM1 expression. Arsenic trioxide (ATO) reduced macrophage infiltration into the TME and impaired IL-1β secretion by macrophages. The combinatorial use of ATO enhanced the in vivo efficacy of DTX in a mouse model, which may provide a revolutionary approach to overcoming acquired therapeutic resistance in HNSCC.
Collapse
Affiliation(s)
- Ching-Yun Hsieh
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
| | - Ching-Chan Lin
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
| | - Yu-Wen Huang
- Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan
| | - Jong-Hang Chen
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
| | - Yung-An Tsou
- Department of Otolaryngology-Head and Neck Surgery and
| | - Ling-Chu Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.,Chinese Medicinal Research and Development Center, China Medical University Hospital, and,Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
| | - Chi-Chen Fan
- Department of Research and Development, Marker Exploration Corporation, Taipei, Taiwan.,Department of Medical Laboratory Science and Biotechnology, Yuanpei University of Medical Technology, Hsinchu, Taiwan
| | - Chen-Yuan Lin
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
| |
Collapse
|
7
|
Hsieh CY, Chang WC, Lin CC, Chen JH, Lin CY, Liu CH, Lin C, Hung MC. Combination treatment of arsenic trioxide and osimertinib in recurrent and metastatic head and neck squamous cell carcinoma. Am J Cancer Res 2022; 12:5049-5061. [PMID: 36504903 PMCID: PMC9729903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Accepted: 10/30/2022] [Indexed: 12/15/2022] Open
Abstract
Recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) represents an advanced stage of the disease and frequently shows resistance to these current treatments, including platinum chemotherapy, cetuximab plus chemotherapy, and checkpoint inhibitors. EGFR overexpression and TP53 mutation are the most frequent genetic changes in patients with HNSCC. On the basis of this genetic feature, we proposed a combinatorial treatment using the EGFR tyrosine kinase inhibitor osimertinib (AZD) and arsenic trioxide (ATO) for compassionate use. The patient obtained treatment response and progression-free survival for about six months. In vitro mechanical verifications showed that ATO and AZD combination (ATO/AZD) significantly increased intracellular ROS levels and DNA damage. Additionally, ATO/AZD decreases the expression and activity of breast cancer type 1 susceptibility protein (BRCA1) and polo-like kinase 1 (PLK1), thereby impairing Rad51 recruitment to DNA double-strand lesion for repair and may ultimately cause tumor cell death. In conclusion, this study provides a concrete experience and an alternate strategy of ATO/AZD therapy for patients with R/M HNSCC.
Collapse
Affiliation(s)
- Ching-Yun Hsieh
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical UniversityTaichung 40402, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical UniversityTaichung 40402, Taiwan
| | - Ching-Chan Lin
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical UniversityTaichung 40402, Taiwan
| | - Jong-Hang Chen
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical UniversityTaichung 40402, Taiwan
| | - Chen-Yuan Lin
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical UniversityTaichung 40402, Taiwan
| | - Chia-Hua Liu
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical UniversityTaichung 40402, Taiwan
| | - Chen Lin
- Center for Molecular Medicine, China Medical University Hospital, China Medical UniversityTaichung 40402, Taiwan
| | - Mien-Chie Hung
- Center for Molecular Medicine, China Medical University Hospital, China Medical UniversityTaichung 40402, Taiwan,Research Center for Cancer Biology, China Medical UniversityTaichung 40402, Taiwan,College of Medicine, Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 40402, Taiwan,Department of Biotechnology, Asia UniversityTaichung 40402, Taiwan
| |
Collapse
|
8
|
Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 2022; 3:1211-1227. [PMID: 36253486 PMCID: PMC9586872 DOI: 10.1038/s43018-022-00438-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Accepted: 08/24/2022] [Indexed: 12/28/2022]
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors have demonstrated promising clinical activity in multiple cancers. However, resistance to PARP inhibitors remains a substantial clinical challenge. In the present study, we report that anaplastic lymphoma kinase (ALK) directly phosphorylates CDK9 at tyrosine-19 to promote homologous recombination (HR) repair and PARP inhibitor resistance. Phospho-CDK9-Tyr19 increases its kinase activity and nuclear localization to stabilize positive transcriptional elongation factor b and activate polymerase II-dependent transcription of HR-repair genes. Conversely, ALK inhibition increases ubiquitination and degradation of CDK9 by Skp2, an E3 ligase. Notably, combination of US Food and Drug Administration-approved ALK and PARP inhibitors markedly reduce tumor growth and improve survival of mice in PARP inhibitor-/platinum-resistant tumor xenograft models. Using human tumor biospecimens, we further demonstrate that phosphorylated ALK (p-ALK) expression is associated with resistance to PARP inhibitors and positively correlated with p-Tyr19-CDK9 expression. Together, our findings support a biomarker-driven, combinatorial treatment strategy involving ALK and PARP inhibitors to induce synthetic lethality in PARP inhibitor-/platinum-resistant tumors with high p-ALK-p-Tyr19-CDK9 expression.
Collapse
Affiliation(s)
- Yu-Yi Chu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Mei-Kuang Chen
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- UT Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yongkun Wei
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Heng-Huan Lee
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Weiya Xia
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Ying-Nai Wang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Clinton Yam
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- UT Health Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Jennifer L Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Hung-Ling Wang
- Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Wei-Chao Chang
- Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Hirohito Yamaguchi
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Zhou Jiang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chunxiao Liu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Ching-Fei Li
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Lei Nie
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Li-Chuan Chan
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yuan Gao
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Shao-Chun Wang
- Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Jinsong Liu
- Department of Anatomic Pathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Shannon N Westin
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sanghoon Lee
- Department of Systems Biology, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Anil K Sood
- Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Liuqing Yang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Gabriel N Hortobagyi
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Dihua Yu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Mien-Chie Hung
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Graduate Institute of Biomedical Sciences, Research Center for Cancer Biology, and Center for Molecular Medicine, China Medical University, Taichung, Taiwan.
- Department of Biotechnology, Asia University, Taichung, Taiwan.
| |
Collapse
|
9
|
Wang WJ, Chen Y, Su WC, Liu YY, Shen WJ, Chang WC, Huang ST, Lin CW, Wang YC, Yang CS, Hou MH, Chou YC, Wu YC, Wang SC, Hung MC. Peimine inhibits variants of SARS-CoV-2 cell entry via blocking the interaction between viral spike protein and ACE2. J Food Biochem 2022; 46:e14354. [PMID: 35894128 PMCID: PMC9353385 DOI: 10.1111/jfbc.14354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2022] [Revised: 07/04/2022] [Accepted: 07/13/2022] [Indexed: 11/29/2022]
Abstract
Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several vaccines against SARS-CoV-2 have been approved; however, variants of concern (VOCs) can evade vaccine protection. Therefore, developing small compound drugs that directly block the interaction between the viral spike glycoprotein and ACE2 is urgently needed to provide a complementary or alternative treatment for COVID-19 patients. We developed a viral infection assay to screen a library of approximately 126 small molecules and showed that peimine inhibits VOCs viral infections. In addition, a fluorescence resonance energy transfer (FRET) assay showed that peimine suppresses the interaction of spike and ACE2. Molecular docking analysis revealed that peimine exhibits a higher binding affinity for variant spike proteins and is able to form hydrogen bonds with N501Y in the spike protein. These results suggest that peimine, a compound isolated from Fritillaria, may be a potent inhibitor of SARS-CoV-2 variant infection. PRACTICAL APPLICATIONS: In this study, we identified a naturally derived compound of peimine, a major bioactive alkaloid extracted from Fritillaria, that could inhibit SARS-CoV-2 variants of concern (VOCs) viral infection in 293T/ACE2 and Calu-3 lung cells. In addition, peimine blocks viral entry through interruption of spike and ACE2 interaction. Moreover, molecular docking analysis demonstrates that peimine has a higher binding affinity on N501Y in the spike protein. Furthermore, we found that Fritillaria significantly inhibits SARS-CoV-2 viral infection. These results suggested that peimine and Fritillaria could be a potential functional drug and food for COVID-19 patients.
Collapse
Affiliation(s)
- Wei-Jan Wang
- Department of Biological Science and Technology, China Medical University, Taichung, Taiwan.,Research Center for Cancer Biology, China Medical University, Taichung, Taiwan
| | - Yeh Chen
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.,Gradaute Institute of New Drug Development, China Medical University, Taichung, Taiwan.,New Drug Development Center, China Medical University, Taichung, Taiwan
| | - Wen-Chi Su
- International Master's Program of Biomedical Sciences, China Medical University, Taichung, Taiwan.,Research Center for Emerging Viruses, China Medical University Hospital, Taichung, Taiwan
| | - Yen-Yi Liu
- Department of Public Health, China Medical University, Taichung, Taiwan
| | - Wan-Jou Shen
- College of Medicine, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
| | - Sheng-Teng Huang
- School of Chinese Medicine, China Medical University, Taichung, Taiwan.,Department of Chinese Medicine, Research Cancer Center for Traditional Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.,Department of Medical Research, China Medical University Hospital, Taichung, Taiwan.,An-Nan Hospital, China Medical University, Tainan, Taiwan
| | - Cheng-Wen Lin
- Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan
| | - Yu-Chuan Wang
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.,Gradaute Institute of New Drug Development, China Medical University, Taichung, Taiwan.,New Drug Development Center, China Medical University, Taichung, Taiwan
| | - Chia-Shin Yang
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.,Gradaute Institute of New Drug Development, China Medical University, Taichung, Taiwan.,New Drug Development Center, China Medical University, Taichung, Taiwan
| | - Mei-Hui Hou
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.,Gradaute Institute of New Drug Development, China Medical University, Taichung, Taiwan.,New Drug Development Center, China Medical University, Taichung, Taiwan
| | - Yu-Chi Chou
- RNA Technology Platform and Gene Manipulation Core, Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei, Taiwan
| | - Yang-Chang Wu
- Chinese Medicine Research and Development Center, China Medical University Hospital, China Medical University, Taichung, Taiwan.,Graduate Institute of Integrated Medicine, College of Chinese Medicine, China Medical University, Taichung, Taiwan.,Department of Medical Laboratory Science and Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan
| | - Shao-Chun Wang
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.,College of Medicine, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.,Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan.,Cancer Biology and Drug Discovery Ph.D. Program, China Medical University, Taichung, Taiwan.,Department of Biotechnology, Asia University, Taichung, Taiwan
| | - Mien-Chie Hung
- Research Center for Cancer Biology, China Medical University, Taichung, Taiwan.,College of Medicine, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.,Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan.,Department of Biotechnology, Asia University, Taichung, Taiwan
| |
Collapse
|
10
|
Wu CS, Chiang HM, Chen Y, Chen CY, Chen HF, Su WC, Wang WJ, Chou YC, Chang WC, Wang SC, Hung MC. Prospects of Coffee Leaf against SARS-CoV-2 Infection. Int J Biol Sci 2022; 18:4677-4689. [PMID: 35874948 PMCID: PMC9305275 DOI: 10.7150/ijbs.76058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Accepted: 06/27/2022] [Indexed: 11/24/2022] Open
Abstract
In the current climate, many countries are in dire need of effective preventive methods to curb the Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) pandemic. The purpose of this research is to screen and explore natural plant extracts that have the potential to against SARS-CoV-2 and provide alternative options for SARS-CoV-2 prevention and hand sanitizer or spray-like disinfectants. We first used Spike-ACE2 ELISA and TMPRSS2 fluorescence resonance energy transfer (FRET) assays to screen extracts from agricultural by-products from Taiwan with the potential to impede SARS-CoV-2 infection. Next, the SARS-CoV-2 pseudo-particles (Vpp) infection assay was tested to validate the effectiveness. We identified an extract from coffee leaf (Coffea Arabica), a natural plant that effectively inhibited wild-type SARS-CoV-2, and five Variants of Concern (Alpha, Beta, Gamma, Delta, and Omicron strain) from entering host cells. In an attempt to apply coffee leaf extract for hand sanitizer or spray-like disinfectants, we designed a skin-like gelatin membrane experiment. We showed that the high concentration of coffee leaf extract on the skin surface could block SARS-CoV-2 into cells more potently than 75% Ethanol, a standard disinfectant to inactivate SARS-CoV-2. Finally, LC-HRMS analysis was used to identify compounds such as caffeine, chlorogenic acid (CGA), quinic acid, and mangiferin that are associated with an anti-SARS-CoV-2 activity. Our results demonstrated that coffee leaf extract, an agricultural by-product effectively inhibits SARS-CoV-2 Vpp infection through an ACE2-dependent mechanism and may be utilized to develop products against SARS-CoV-2 infection.
Collapse
Affiliation(s)
- Chen-Shiou Wu
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan
| | - Hsiu-Mei Chiang
- Department of Cosmeceutics, China Medical University, Taichung 406040, Taiwan
| | - Yeh Chen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.,Institute of New Drug Development, China Medical University, Taichung 406040, Taiwan.,Research Center for Cancer Biology, China Medical University, Taichung 406040, Taiwan
| | - Chung-Yu Chen
- Research Center for Cancer Biology, China Medical University, Taichung 406040, Taiwan
| | - Hsiao-Fan Chen
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan
| | - Wen-Chi Su
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.,International Master's Program of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.,Department of Medical Research, China Medical University Hospital, Taichung 404332, Taiwan
| | - Wei-Jan Wang
- Research Center for Cancer Biology, China Medical University, Taichung 406040, Taiwan.,Department of Biological Science and Technology, China Medical University, Taichung 406040, Taiwan
| | - Yu-Chi Chou
- Biomedical Translation Research Center (BioTReC), Academia Sinica, Taipei 115024, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung 404332, Taiwan
| | - Shao-Chun Wang
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.,Research Center for Cancer Biology, China Medical University, Taichung 406040, Taiwan.,Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung 404332, Taiwan.,Department of Biotechnology, Asia University, Taichung, 41354 Taiwan
| | - Mien-Chie Hung
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406040, Taiwan.,Research Center for Cancer Biology, China Medical University, Taichung 406040, Taiwan.,Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung 404332, Taiwan.,Department of Biotechnology, Asia University, Taichung, 41354 Taiwan
| |
Collapse
|
11
|
Wong SMY, Suen YN, Wong CWC, Chan SKW, Hui CLM, Chang WC, Lee EHM, Cheng CPW, Ho GCL, Lo GG, Leung EYL, Yeung PKMA, Chen S, Honer WG, Mak HKF, Sham PC, McKenna PJ, Pomarol-Clotet E, Veronese M, Howes OD, Chen EYH. Striatal dopamine synthesis capacity and its association with negative symptoms upon resolution of positive symptoms in first-episode schizophrenia and delusional disorder. Psychopharmacology (Berl) 2022; 239:2133-2141. [PMID: 35211769 DOI: 10.1007/s00213-022-06088-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 02/10/2022] [Indexed: 12/21/2022]
Abstract
RATIONALE How striatal dopamine synthesis capacity (DSC) contributes to the pathogenesis of negative symptoms in first-episode schizophrenia (SZ) and delusional disorder (DD) has seldom been explored. As negative symptoms during active psychotic episodes can be complicated by secondary influences, such as positive symptoms, longitudinal investigations may help to clarify the relationship between striatal DSC and negative symptoms and differentiate between primary and secondary negative symptoms. OBJECTIVE A longitudinal study was conducted to examine whether baseline striatal DSC would be related to negative symptoms at 3 months in first-episode SZ and DD patients. METHODS Twenty-three first-episode age- and gender-matched patients (11 DD and 12 SZ) were consecutively recruited through an early intervention service for psychosis in Hong Kong. Among them, 19 (82.6%) patients (9 DD and 10 SZ) were followed up at 3 months. All patients received an 18F-DOPA PET/MR scan at baseline. RESULTS Baseline striatal DSC (Kocc;30-60) was inversely associated with negative symptoms at 3 months in first-episode SZ patients (rs = - 0.80, p = 0.010). This association remained in SZ patients even when controlling for baseline negative, positive, and depressive symptoms, as well as cumulative antipsychotic dosage (β = - 0.69, p = 0.012). Such associations were not observed in first-episode DD patients. Meanwhile, the severity of negative symptoms at 3 months was associated with more positive symptoms in DD patients (rs = 0.74, p = 0.010) and not in SZ patients. CONCLUSIONS These findings highlight the role of striatal DSC in negative symptoms upon resolution of active psychotic episodes among first-episode SZ patients. Baseline striatal dopamine activity may inform future symptom expression with important treatment implications.
Collapse
Affiliation(s)
- Stephanie M Y Wong
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China
| | - Y N Suen
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China
| | - Charlotte W C Wong
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China
| | - Sherry K W Chan
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China.,The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - Christy L M Hui
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China
| | - W C Chang
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China.,The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - Edwin H M Lee
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China
| | - Calvin P W Cheng
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China
| | - Garrett C L Ho
- Hong Kong Sanatorium & Hospital, Happy Valley, Pokfulam, Hong Kong, China
| | - Gladys Goh Lo
- Hong Kong Sanatorium & Hospital, Happy Valley, Pokfulam, Hong Kong, China
| | - Eric Y L Leung
- Hong Kong Sanatorium & Hospital, Happy Valley, Pokfulam, Hong Kong, China
| | - Paul K M Au Yeung
- Hong Kong Sanatorium & Hospital, Happy Valley, Pokfulam, Hong Kong, China
| | - Sirong Chen
- Hong Kong Sanatorium & Hospital, Happy Valley, Pokfulam, Hong Kong, China
| | - William G Honer
- Department of Psychiatry, The University of British Columbia, Vancouver, BC, Canada.,British Columbia Institute of Mental Health and Substance Use Services, Vancouver, Canada
| | - Henry K F Mak
- Department of Diagnostic Radiology, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - P C Sham
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China.,The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong, China
| | - Peter J McKenna
- FIDMAG Hermanas Hospitalarias Research Foundation, Barcelona, Spain
| | | | - Mattia Veronese
- Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK
| | - Oliver D Howes
- Psychosis Studies Department, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.,Institute of Clinical Sciences (ICS), Faculty of Medicine, Imperial College London, London, UK.,MRC London Institute of Medical Sciences, Hammersmith Hospital, London, UK
| | - Eric Y H Chen
- Department of Psychiatry, The University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Pokfulam, Hong Kong, China. .,The State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Pokfulam, Hong Kong, China.
| |
Collapse
|
12
|
Chen M, Gao Y, Xia W, Wang YH, Litton JK, Chu YY, Meric-Bernstam F, Piwnica-Worms H, Arun B, Ahnert JR, Wei Y, Chang WC, Wang HL, Tapia C, Albarracin CT, Wang SC, Wang YN, Hortobagyi GN, Lin C, Yang L, Yu D, Hung MC. Abstract 1792: FGFR3 mediated PARP1 tyrosine 158 phosphorylation promotes PARP inhibitor resistance. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-1792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), which induce DNA damage by inhibiting PARP1 enzymatic activity and trapping PARP on the damaged DNA, are used to eliminate BRCA1/2-mutated (BRCAm) cancer. However, clinical observations suggest that BRCAm tumors develop PARPi resistance. Current strategies to overcome PARPi resistance include impeding multiple DNA repair pathways to induce excessive DNA damage. Here, we propose a novel strategy targeting oncogenic receptor tyrosine kinases to enhance PARP trapping. By developing triple-negative breast cancer (TNBC) cells with acquired talazoparib resistance, we observed a high prevalence of activated fibroblast growth factor receptor 3 (FGFR3) kinase in these cells through kinase antibody array analysis. Mass spectrometry analysis and in vitro kinase assay suggested that FGFR3 phosphorylated PARP1 at tyrosine residues 158 and 176. Biochemistry studies suggested that only PARP1 tyrosine 158 phosphorylation contributes to PARPi resistance in the cells we developed. We then developed a monoclonal antibody against tyrosine 158 phosphorylated PARP1, and found that high-level PARP1 tyrosine 158 phosphorylation positively correlated with PARPi resistance in breast cancer patient-derived xenograft models. We further demonstrated that the combination of FGFR inhibitor and PARPi delayed DNA repair with prolonged PARP trapping. Moreover, synergy between PARPi and FGFR inhibition was observed in multiple TNBC cell lines with PARPi resistance in vitro. The combination of PARPi and FGFR inhibitor also showed synergism in vivo, and treatment with the combination of PARPi and FGFR inhibitor was tolerated in mouse models. These findings reveal that PARP1 tyrosine 158 phosphorylation facilitates resolving of the PARPi-induced PARP-trapping, and that the tyrosine 158 phosphorylated PARP1 may be an effective biomarker to indicate FGFR3 mediated PARPi resistance.
Citation Format: MeiKuang Chen, Yuan Gao, Weiya Xia, Yu-Han Wang, Jennifer K. Litton, Yu-Yi Chu, Funda Meric-Bernstam, Helen Piwnica-Worms, Banu Arun, Jordi Rodon Ahnert, Yongkun Wei, Wei-Chao Chang, Hung-Ling Wang, Coya Tapia, Constance T. Albarracin, Shao-Chun Wang, Ying-Nai Wang, Gabriel N. Hortobagyi, Chunru Lin, Liuqing Yang, Dihua Yu, Mien-Chie Hung. FGFR3 mediated PARP1 tyrosine 158 phosphorylation promotes PARP inhibitor resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1792.
Collapse
Affiliation(s)
- MeiKuang Chen
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Yuan Gao
- 2Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| | - Weiya Xia
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Yu-Yi Chu
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Banu Arun
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Yongkun Wei
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Coya Tapia
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Ying-Nai Wang
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | - Chunru Lin
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Liuqing Yang
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Dihua Yu
- 1The University of Texas MD Anderson Cancer Center, Houston, TX
| | | |
Collapse
|
13
|
Zhao X, Wei Y, Chu YY, Li Y, Hsu JM, Jiang Z, Liu C, Hsu JL, Chang WC, Yang R, Chan LC, Qu J, Zhang S, Ying H, Yu D, Hung MC. Phosphorylation and stabilization of PD-L1 by CK2 suppresses dendritic cell function. Cancer Res 2022; 82:2185-2195. [PMID: 35385574 DOI: 10.1158/0008-5472.can-21-2300] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 02/04/2022] [Accepted: 04/04/2022] [Indexed: 11/16/2022]
Abstract
Targeting immune checkpoints such as programmed cell death 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) has transformed cancer treatment, with durable clinical responses across a wide range of tumor types. However, a high percentage of patients fail to respond to anti-PD-1/PD-L1 treatment. A greater understanding of PD-L1 regulation is critical to improving the clinical response rate of PD-1/PD-L1 blockade. Here, we demonstrate that PD-L1 is phosphorylated and stabilized by casein kinase 2 (CK2) in cancer and dendritic cells. Phosphorylation of PD-L1 at Thr285 and Thr290 by CK2 disrupted PD-L1 binding with speckle-type POZ protein (SPOP), an adaptor protein of the cullin 3 (CUL3) ubiquitin E3 ligase complex, protecting PD-L1 from CUL3-mediated proteasomal degradation. Inhibition of CK2 decreased PD-L1 protein levels by promoting its degradation and resulted in the release of CD80 from dendritic cells to reactivate T-cell function. In a syngeneic mouse model, combined treatment with a CK2 inhibitor and an antibody against T-cell immunoglobulin mucin-3 (Tim-3) suppressed tumor growth and prolonged survival. These findings uncover a mechanism by which PD-L1 is regulated and suggest a potential anti-tumor treatment option to activate dendritic cell function by blocking the CK2-PD-L1 pathway and inhibiting Tim-3.
Collapse
Affiliation(s)
- Xixi Zhao
- MD Anderson Cancer Center, Houston, TX, United States
| | - Yongkun Wei
- MD Anderson Cancer Center, Houston, TX, United States
| | - Yu-Yi Chu
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | | | | | - Zhou Jiang
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Chunxiao Liu
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Jennifer L Hsu
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | | | - Riyao Yang
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Li-Chuan Chan
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | - Jingkun Qu
- Xi'an Jiaotong University, Xi'an, Shaanxi, China
| | - Shuqun Zhang
- Second Affiliated Hospital of Xi'an Jiaotong University, China
| | - Haoqiang Ying
- The University of Texas MD Anderson Cancer Center, Houston, United States
| | - Dihua Yu
- The University of Texas MD Anderson Cancer Center, Houston, TX, United States
| | | |
Collapse
|
14
|
Hsieh CY, Lien MY, Lin CY, Lo WJ, Hua CH, Chang WC, Chiu CF, Lin CC. Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial. BMC Cancer 2022; 22:169. [PMID: 35168547 PMCID: PMC8845344 DOI: 10.1186/s12885-022-09258-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 01/31/2022] [Indexed: 12/14/2022] Open
Abstract
Background The treatment of recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC) remains challenging. Preclinical studies revealed that B cell depletion could modulate the microenvironment and overcome chemoresistance. We conducted a phase I study to evaluate the feasibility and safety of B cell depletion using the anti-CD20 antibody rituximab to treat HNSCC. Methods Ten patients were enrolled in two protocols. The first four patients treated using protocol 1 received rituximab 1000 mg on days −14 and −7, followed by gemcitabine/cisplatin every 3 weeks, and rituximab was administered every 6 months thereafter. Because of disease hyperprogression, protocol 1 was amended to protocol 2, which consisted of the concomitant administration of rituximab 375 mg/m2 and gemcitabine/cisplatin every 3 weeks. Another six patients were enrolled and treated using protocol 2. Results Three patients treated using protocol 1 exhibited rapid disease progression, and the remaining patient could not undergo evaluation after rituximab treatment. Conversely, no unpredicted harm was observed in the six patients treated using protocol 2. Among these patients, one achieved complete response, and two had partial responses. The disease-free durations in these patients were 7.0, 6.2, and 7.1 months, respectively. Immune cell analysis revealed a higher ratio of cytotoxic T cells to regulatory T cells in responders than in non-responders. Conclusions B cell depletion using rituximab alone in patients with HNSCC can cause hyperprogressive disease. Contrarily, the co-administration of rituximab and cisplatin/gemcitabine was feasible and safe. Trial registration ClinicalTrials.gov Identifier: NCT04361409, 24 April 2020, retrospectively registered
Collapse
Affiliation(s)
- Ching-Yun Hsieh
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan
| | - Ming-Yu Lien
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.,School of Medicine, China Medical University, Taichung, Taiwan
| | - Chen-Yuan Lin
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.,School of Pharmacy and Graduate Institute, China Medical University, Taichung, Taiwan
| | - Wen-Jyi Lo
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan
| | - Chung-Hung Hua
- Department of Otorhinolaryngology, China Medical University Hospital, China Medical University, Taichung, 404, Taiwan
| | - Wei-Chao Chang
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Chang-Fang Chiu
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan
| | - Ching-Chan Lin
- Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, China Medical University, 2 Yude Rd, North District, Taichung, 404, Taiwan.
| |
Collapse
|
15
|
Lin YS, Kuo TT, Lo CC, Cheng WC, Chang WC, Tseng GC, Bai ST, Huang YK, Hsieh CY, Hsu HS, Jiang YF, Lin CY, Lai LC, Li XG, Sher YP. ADAM9 functions as a transcriptional regulator to drive angiogenesis in esophageal squamous cell carcinoma. Int J Biol Sci 2021; 17:3898-3910. [PMID: 34671207 PMCID: PMC8495400 DOI: 10.7150/ijbs.65488] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Accepted: 08/29/2021] [Indexed: 11/25/2022] Open
Abstract
Hypoxia and angiogenesis play key roles in the pathogenesis of esophageal squamous cell carcinoma (ESCC), but regulators linking these two pathways to drive tumor progression remain elusive. Here we provide evidence of ADAM9's novel function in ESCC progression. Increasing expression of ADAM9 was correlated with poor clinical outcomes in ESCC patients. Suppression of ADAM9 function diminished ESCC cell migration and in vivo metastasis in ESCC xenograft mouse models. Using cellular fractionation and imaging, we found a fraction of ADAM9 was present in the nucleus and was uniquely associated with gene loci known to be linked to the angiogenesis pathway demonstrated by genome-wide ChIP-seq. Mechanistically, nuclear ADAM9, triggered by hypoxia-induced translocation, functions as a transcriptional repressor by binding to promoters of genes involved in the negative regulation of angiogenesis, and thereby promotes tumor angiogenesis in plasminogen/plasmin pathway. Moreover, ADAM9 suppresses plasminogen activator inhibitor-1 gene transcription by interacting with its transcription factors at the promoter. Our findings uncover a novel regulatory mechanism of ADAM9 as a transcriptional regulator in angiogenesis and highlight ADAM9 as a promising therapeutic target for ESCC treatment.
Collapse
Affiliation(s)
- Yu-Sen Lin
- Graduate Institute of Clinical Medical Science, China Medical University, Taichung 404, Taiwan.,Division of Thoracic Surgery, China Medical University Hospital, Taichung 404, Taiwan
| | - Ting-Ting Kuo
- Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan
| | - Chia-Chien Lo
- Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan
| | - Wei-Chung Cheng
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan
| | - Guan-Chin Tseng
- Department of Anatomic Pathology, Nantou Hospital of the Ministry of Health and Welfare, Nantou 540, Taiwan
| | - Shih-Ting Bai
- Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan
| | - Yu-Kai Huang
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan
| | - Chih-Ying Hsieh
- Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan
| | - Han-Shui Hsu
- Division of Thoracic Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei 112, Taiwan.,Institute of Emergency and Care Medicine, School of Medicine, National Yang-Ming University, Taipei 112, Taiwan
| | - Yi-Fan Jiang
- Graduate Institute of Molecular and Comparative Pathobiology, School of Veterinary Medicine, National Taiwan University, Taipei 106, Taiwan
| | - Chen-Yuan Lin
- School of Pharmacy, China Medical University, Taichung 404, Taiwan.,Division of Hematology and Oncology, China Medical University Hospital, Taichung 404, Taiwan
| | - Liang-Chuan Lai
- Graduate Institute of Physiology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
| | - Xing-Guo Li
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan
| | - Yuh-Pyng Sher
- Graduate Institute of Clinical Medical Science, China Medical University, Taichung 404, Taiwan.,Center for Molecular Medicine, China Medical University Hospital, Taichung 404, Taiwan.,Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.,Chinese Medicine Research Center, China Medical University, Taichung 404, Taiwan
| |
Collapse
|
16
|
Zhang L, Yao J, Wei Y, Zhou Z, Li P, Qu J, Badu-Nkansah A, Yuan X, Huang YW, Fukumura K, Mao X, Chang WC, Saunus J, Lakhani S, Huse JT, Hung MC, Yu D. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Sci Transl Med 2021; 12:12/545/eaaz5387. [PMID: 32461334 DOI: 10.1126/scitranslmed.aaz5387] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 04/15/2020] [Indexed: 12/12/2022]
Abstract
The functions of immune cells in brain metastases are unclear because the brain has traditionally been considered "immune privileged." However, we found that a subgroup of immunosuppressive neutrophils is recruited into the brain, enabling brain metastasis development. In brain metastatic cells, enhancer of zeste homolog 2 (EZH2) is highly expressed and phosphorylated at tyrosine-696 (pY696)-EZH2 by nuclear-localized Src tyrosine kinase. Phosphorylation of EZH2 at Y696 changes its binding preference from histone H3 to RNA polymerase II, which consequently switches EZH2's function from a methyltransferase to a transcription factor that increases c-JUN expression. c-Jun up-regulates protumorigenic inflammatory cytokines, including granulocyte colony-stimulating factor (G-CSF), which recruits Arg1+- and PD-L1+ immunosuppressive neutrophils into the brain to drive metastasis outgrowth. G-CSF-blocking antibodies or immune checkpoint blockade therapies combined with Src inhibitors impeded brain metastasis in multiple mouse models. These findings indicate that pY696-EZH2 can function as a methyltransferase-independent transcription factor to facilitate the brain infiltration of immunosuppressive neutrophils, which could be clinically targeted for brain metastasis treatment.
Collapse
Affiliation(s)
- Lin Zhang
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.,MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA
| | - Jun Yao
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Yongkun Wei
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Zhifen Zhou
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Ping Li
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Jingkun Qu
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Akosua Badu-Nkansah
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Xiangliang Yuan
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Yu-Wen Huang
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.,Center for Molecular Medicine, China Medical University, Taichung 40402, Taiwan
| | - Kazutaka Fukumura
- Department of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Xizeng Mao
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University, Taichung 40402, Taiwan
| | - Jodi Saunus
- Faculty of Medicine, University of Queensland, St Lucia, QLD 4072, Australia
| | - Sunil Lakhani
- Faculty of Medicine, University of Queensland, St Lucia, QLD 4072, Australia.,Pathology Queensland, The Royal Brisbane & Women's Hospital, Herston, QLD 4029, Australia
| | - Jason T Huse
- Department of Pathology and Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Mien-Chie Hung
- Center for Molecular Medicine, China Medical University, Taichung 40402, Taiwan
| | - Dihua Yu
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. .,MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX 77030, USA.,Center for Molecular Medicine, China Medical University, Taichung 40402, Taiwan
| |
Collapse
|
17
|
Wong SMY, Hui CLM, Wong CSM, Suen YN, Chan SKW, Lee EHM, Chang WC, Chen EYH. Mental Health Risks after Repeated Exposure to Multiple Stressful Events during Ongoing Social Unrest and Pandemic in Hong Kong: The Role of Rumination: Risques pour la santé mentale après une exposition répétée à de multiples événements stressants d'agitation sociale durable et de pandémie à Hong Kong: le rôle de la rumination. Can J Psychiatry 2021; 66:577-585. [PMID: 33317325 PMCID: PMC8138734 DOI: 10.1177/0706743720979920] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVES The co-occurrence of different classes of population-level stressors, such as social unrest and public health crises, is common in contemporary societies. Yet, few studies explored their combined mental health impact. The aim of this study was to examine the impact of repeated exposure to social unrest-related traumatic events (TEs), coronavirus disease 2019 (COVID-19) pandemic-related events (PEs), and stressful life events (SLEs) on post-traumatic stress disorder (PTSD) and depressive symptoms, and the potential mediating role of event-based rumination (rumination of TEs-related anger, injustice, guilt, and insecurity) between TEs and PTSD symptoms. METHODS Community members in Hong Kong who had utilized a screening tool for PTSD and depressive symptoms were invited to complete a survey on exposure to stressful events and event-based rumination. RESULTS A total of 10,110 individuals completed the survey. Hierarchical regression analysis showed that rumination, TEs, and SLEs were among the significant predictors for PTSD symptoms (all P < 0.001), accounting for 32% of the variance. For depression, rumination, SLEs, and PEs were among the significant predictors (all P < 0.001), explaining 24.9% of the variance. Two-way analysis of variance of different recent and prior TEs showed significant dose-effect relationships. The effect of recent TEs on PTSD symptoms was potentiated by prior TEs (P = 0.005). COVID-19 PEs and prior TEs additively contributed to PTSD symptoms, with no significant interaction (P = 0.94). Meanwhile, recent TEs were also potentiated by SLEs (P = 0.002). The effects of TEs on PTSD symptoms were mediated by rumination (β = 0.38, standard error = 0.01, 95% confidence interval: 0.36 to 0.41), with 40.4% of the total effect explained. All 4 rumination subtypes were significant mediators. CONCLUSIONS Prior and ongoing TEs, PEs, and SLEs cumulatively exacerbated PTSD and depressive symptoms. The role of event-based rumination and their interventions should be prioritized for future research.
Collapse
Affiliation(s)
- Stephanie M Y Wong
- Department of Psychiatry, LKS Faculty of Medicine, 25809University of Hong Kong, Hong Kong
| | - Christy L M Hui
- Department of Psychiatry, LKS Faculty of Medicine, 25809University of Hong Kong, Hong Kong
| | - Corine S M Wong
- Department of Psychiatry, LKS Faculty of Medicine, 25809University of Hong Kong, Hong Kong
| | - Y N Suen
- Department of Psychiatry, LKS Faculty of Medicine, 25809University of Hong Kong, Hong Kong
| | - Sherry K W Chan
- Department of Psychiatry, LKS Faculty of Medicine, 25809University of Hong Kong, Hong Kong.,State Key Laboratory of Brain and Cognitive Sciences, 25809University of Hong Kong, Hong Kong
| | - Edwin H M Lee
- Department of Psychiatry, LKS Faculty of Medicine, 25809University of Hong Kong, Hong Kong
| | - W C Chang
- Department of Psychiatry, LKS Faculty of Medicine, 25809University of Hong Kong, Hong Kong.,State Key Laboratory of Brain and Cognitive Sciences, 25809University of Hong Kong, Hong Kong
| | - Eric Y H Chen
- Department of Psychiatry, LKS Faculty of Medicine, 25809University of Hong Kong, Hong Kong.,State Key Laboratory of Brain and Cognitive Sciences, 25809University of Hong Kong, Hong Kong
| |
Collapse
|
18
|
Huang ST, Chen Y, Chang WC, Chen HF, Lai HC, Lin YC, Wang WJ, Wang YC, Yang CS, Wang SC, Hung MC. Scutellaria barbata D. Don Inhibits the Main Proteases (M pro and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Viruses 2021; 13:826. [PMID: 34063247 PMCID: PMC8147405 DOI: 10.3390/v13050826] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 04/28/2021] [Accepted: 04/29/2021] [Indexed: 12/15/2022] Open
Abstract
In late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic emerged to severely impact the global population, creating an unprecedented need for effective treatments. This study aims to investigate the potential of Scutellaria barbata D. Don (SB) as a treatment for SARS-CoV-2 infection through the inhibition of the proteases playing important functions in the infection by SARS-CoV-2. FRET assay was applied to investigate the inhibitory effects of SB on the two proteases involved in SARS-CoV-2 infection, Mpro and TMPRSS2. Additionally, to measure the potential effectiveness of SB treatment on infection inhibition, cellular models based on the Calu3 and VeroE6 cells and their TMPRSS2- expressing derivatives were assessed by viral pseudoparticles (Vpp) infection assays. The experimental approaches were conjugated with LC/MS analyses of the aqueous extracts of SB to identify the major constituent compounds, followed by a literature review to determine the potential active components of the inhibitory effects on protease activities. Our results showed that SB extracts inhibited the enzyme activities of Mpro and TMPRSS2. Furthermore, SB extracts effectively inhibited SARS-CoV-2 Vpp infection through a TMPRSS2-dependent mechanism. The aqueous extract analysis identified six major constituent compounds present in SB. Some of them have been known associated with inhibitory activities of TMPRSS2 or Mpro. Thus, SB may effectively prevent SARS-CoV-2 infection and replication through inhibiting Mpro and TMPRSS2 protease activities.
Collapse
Affiliation(s)
- Sheng-Teng Huang
- School of Chinese Medicine, China Medical University, Taichung 40402, Taiwan;
- Department of Chinese Medicine, China Medical University Hospital, Taichung 40402, Taiwan; (H.-C.L.); (Y.-C.L.)
- Research Cancer Center for Traditional Chinese Medicine, Department of Medical Research, China Medical University Hospital, Taichung 40402, Taiwan
- An-Nan Hospital, China Medical University, Tainan 709, Taiwan
| | - Yeh Chen
- Research Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan; (Y.C.); (H.-F.C.); (S.-C.W.)
- New Drug Development Center, China Medical University, Taichung 40402, Taiwan
- Graduate Institute of New Drug Development, China Medical University, Taichung 40402, Taiwan; (Y.-C.W.); (C.-S.Y.)
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, Taichung 40402, Taiwan;
| | - Hsiao-Fan Chen
- Research Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan; (Y.C.); (H.-F.C.); (S.-C.W.)
- New Drug Development Center, China Medical University, Taichung 40402, Taiwan
| | - Hsiang-Chun Lai
- Department of Chinese Medicine, China Medical University Hospital, Taichung 40402, Taiwan; (H.-C.L.); (Y.-C.L.)
| | - Yu-Chun Lin
- Department of Chinese Medicine, China Medical University Hospital, Taichung 40402, Taiwan; (H.-C.L.); (Y.-C.L.)
| | - Wei-Jan Wang
- Department of Biological Science and Technology, China Medical University, Taichung 40402, Taiwan;
- Graduate Institute of Biomedical Sciences, China Medical University Taichung 40402, Taiwan
| | - Yu-Chuan Wang
- Graduate Institute of New Drug Development, China Medical University, Taichung 40402, Taiwan; (Y.-C.W.); (C.-S.Y.)
| | - Chia-Shin Yang
- Graduate Institute of New Drug Development, China Medical University, Taichung 40402, Taiwan; (Y.-C.W.); (C.-S.Y.)
| | - Shao-Chun Wang
- Research Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan; (Y.C.); (H.-F.C.); (S.-C.W.)
- New Drug Development Center, China Medical University, Taichung 40402, Taiwan
- Center for Molecular Medicine, China Medical University Hospital, Taichung 40402, Taiwan;
- Graduate Institute of Biomedical Sciences, China Medical University Taichung 40402, Taiwan
- Department of Biotechnology, Asia University, Taichung 41354, Taiwan
| | - Mien-Chie Hung
- Research Center for Cancer Biology, China Medical University, Taichung 40402, Taiwan; (Y.C.); (H.-F.C.); (S.-C.W.)
- New Drug Development Center, China Medical University, Taichung 40402, Taiwan
- Center for Molecular Medicine, China Medical University Hospital, Taichung 40402, Taiwan;
- Graduate Institute of Biomedical Sciences, China Medical University Taichung 40402, Taiwan
- Department of Biotechnology, Asia University, Taichung 41354, Taiwan
| |
Collapse
|
19
|
Wong SMY, Hui CLM, Wong CSM, Suen YN, Chan SKW, Lee EHM, Chang WC, Chen EYH. Prospective prediction of PTSD and depressive symptoms during social unrest and COVID-19 using a brief online tool. Psychiatry Res 2021; 298:113773. [PMID: 33545423 PMCID: PMC9754713 DOI: 10.1016/j.psychres.2021.113773] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/22/2020] [Accepted: 01/27/2021] [Indexed: 12/15/2022]
Abstract
Large-scale protracted population stressors, such as social unrest and the coronavirus disease 2019 (COVID-19), are associated with increased symptoms of post-traumatic stress disorder (PTSD) and depression. Cost-effective mental health screening is prerequisite for timely intervention. We developed an online tool to identify prospective predictors of PTSD and depressive symptoms in the context of co-occurring social unrest and COVID-19 in Hong Kong. 150 participants completed baseline and follow-up assessments, with a median duration of 29 days. Three logistic regression models were constructed to assess its discriminative power in predicting PTSD and depressive symptoms at one month. Receiver-operating characteristic analysis was performed for each model to determine their optimal decision thresholds. Sensitivity and specificity of the models were 87.1% and 53.8% for probable PTSD, 77.5% and 63.3% for high-risk depressive symptoms, and 44.7% and 96.4% for no significant depressive symptoms. The models performed well in discriminating outcomes (AUCs range: 0.769-0.811). Probable PTSD was predicted by social unrest-related traumatic events, high rumination, and low resilience. Rumination and resilience also predicted high-risk and no significant depressive symptoms, with COVID-19-related events also predicting no significant depression risk. Accessible screening of probable mental health outcomes with good predictive capability may be important for early intervention opportunities.
Collapse
Affiliation(s)
- Stephanie MY Wong
- Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
| | - Christy LM Hui
- Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
| | - Corine SM Wong
- Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
| | - YN Suen
- Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
| | - Sherry KW Chan
- Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong,State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong
| | - Edwin HM Lee
- Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong
| | - WC Chang
- Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong,State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong
| | - Eric YH Chen
- Department of Psychiatry, LKS Faculty of Medicine, University of Hong Kong, Hong Kong,Corresponding author at: Department of Psychiatry, University of Hong Kong, 2/F New Clinical Building, Queen Mary Hospital, Pokfulam Road, Hong Kong
| |
Collapse
|
20
|
Wong SMY, Hui CLM, Wong CSM, Suen YN, Chan SKW, Lee EHM, Chang WC, Wong GHY, Chen EYH. Induced ideas of reference during social unrest and pandemic in Hong Kong. Schizophr Res 2021; 229:46-52. [PMID: 33618286 DOI: 10.1016/j.schres.2021.01.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/28/2020] [Revised: 01/05/2021] [Accepted: 01/29/2021] [Indexed: 12/18/2022]
Abstract
Ideas of reference (IOR) are often implicated in predicting psychosis onset. They have been conceptualized to present on a continuum, from oversensitive psychological reactions to delusional thoughts. It is however unknown to what extent IOR may be triggered by collective environmental stress. We obtained timely data from 9873 individuals to assess IOR in relation to trauma exposure in the 2019-2020 social unrest in Hong Kong. Two levels of IOR are distinguished: attenuated IOR (IOR-A), being the experience of feeling particularly referred to within a group; and exclusive IOR (IOR-E), the experience of feeling exclusively referred to while others are not. Logistic regressions showed that event-based rumination was a shared predictor for IOR-A (OR = 1.07, CI = 1.03-1.10) and IOR-E (OR = 1.09, CI = 1.02-1.17). For IOR-A, three categories of social unrest-related traumatic events (TEs) were significant predictors, including being attacked or having experienced sexual violence (OR = 4.14, CI = 1.93-8.85), being arrested (OR = 4.48, CI = 1.99-10.10), and being verbally abused (OR = 2.66, CI = 1.28-5.53). Being arrested was significant for IOR-E (OR = 3.87, CI = 1.03-14.52), though not when rumination was included. Education level also significantly predicted IOR-E (OR = 0.72, CI = 0.52-0.99). Further analysis revealed that rumination significantly mediated between TEs and IOR severity (β = 0.26, SE = 0.01, CI = 0.24-0.28). The findings are consistent with the hypothesis that IOR-A and IOR-E occur as levels on a continuum, but each has some distinctive correlates. Extrinsic events may play a more prominent role in IOR-A, while intrinsic factors, such as cognitive capacity, may play a more prominent role in IOR-E. The involvement of rumination across the IOR spectrum suggests an opportunity for intervention.
Collapse
Affiliation(s)
- Stephanie M Y Wong
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
| | - Christy L M Hui
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
| | - Corine S M Wong
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
| | - Y N Suen
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
| | - Sherry K W Chan
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong
| | - Edwin H M Lee
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong
| | - W C Chang
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong
| | - Gloria H Y Wong
- Department of Social Work and Social Administration, The University of Hong Kong, Hong Kong
| | - Eric Y H Chen
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong.
| |
Collapse
|
21
|
Tsou YA, Chang WC, Lin CD, Chang RL, Tsai MH, Shih LC, Staniczek T, Wu TF, Hsu HY, Chang WD, Lai CH, Chen CM. Metformin Increases Survival in Hypopharyngeal Cancer Patients with Diabetes Mellitus: Retrospective Cohort Study and Cell-Based Analysis. Pharmaceuticals (Basel) 2021; 14:ph14030191. [PMID: 33652909 PMCID: PMC7996771 DOI: 10.3390/ph14030191] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Revised: 02/21/2021] [Accepted: 02/23/2021] [Indexed: 12/15/2022] Open
Abstract
Hypopharyngeal squamous cell carcinoma (HSCC) is usually diagnosed at an advanced stage, leading to a poor prognosis. Even after improvement of surgical techniques, chemotherapy, and radiation technology, the survival rate of HSCC remains poor. Metformin, which is commonly used for type 2 diabetes mellitus (DM), has been suggested to reduce the risk of various cancer types. However, only a few clinical studies mentioned the relationship between metformin use and HSCC. Hence, the aim of this study was to elucidate the specific effect and mechanism of action of metformin in hypopharyngeal cancer. We first assessed whether metformin use has an effect on hypopharyngeal cancer patients with DM by conducting a retrospective cohort study. Our results showed that DM hypopharyngeal cancer patients who used metformin exhibited significantly better overall survival rates than that without metformin treatment. The cell-based analysis further indicated that metformin treatment regulated p38/JNK pathway to reduce Cyclin D1 and Bcl-2 expressions. In addition, metformin activated the pathways of AMPKα and MEK/ERK to phosphorylate p27(Thr198) and reduce mTOR phosphorylation in cells. These actions direct cells toward G1 cell cycle arrest, apoptosis, and autophagy. Our results, through combining a clinical cohort analysis with an in vitro study, demonstrate that metformin can be used for drug repositioning in the treatment of DM patients with hypopharyngeal cancer.
Collapse
Affiliation(s)
- Yung-An Tsou
- Department of Otolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 406, Taiwan; (Y.-A.T.); (C.-D.L.); (M.-H.T.); (L.-C.S.); (T.-F.W.)
- Department of Life Sciences, Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan;
| | - Wei-Chao Chang
- Center for Molecular Medicine, Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406, Taiwan; (W.-C.C.); (H.-Y.H.)
| | - Chia-Der Lin
- Department of Otolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 406, Taiwan; (Y.-A.T.); (C.-D.L.); (M.-H.T.); (L.-C.S.); (T.-F.W.)
| | - Ro-Lin Chang
- Department of Life Sciences, Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan;
| | - Ming-Hsui Tsai
- Department of Otolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 406, Taiwan; (Y.-A.T.); (C.-D.L.); (M.-H.T.); (L.-C.S.); (T.-F.W.)
| | - Liang-Chun Shih
- Department of Otolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 406, Taiwan; (Y.-A.T.); (C.-D.L.); (M.-H.T.); (L.-C.S.); (T.-F.W.)
- Center for Molecular Medicine, Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406, Taiwan; (W.-C.C.); (H.-Y.H.)
| | - Theresa Staniczek
- Department of Dermatology, Venereology and Allergology, University Medical Center and Medical Faculty Mannheim, Center of Excellence in Dermatology, Heidelberg University, 68167 Mannheim, Germany;
| | - Tsu-Fang Wu
- Department of Otolaryngology-Head and Neck Surgery, China Medical University Hospital, Taichung 406, Taiwan; (Y.-A.T.); (C.-D.L.); (M.-H.T.); (L.-C.S.); (T.-F.W.)
| | - Hui-Ying Hsu
- Center for Molecular Medicine, Graduate Institute of Biomedical Sciences, China Medical University, Taichung 406, Taiwan; (W.-C.C.); (H.-Y.H.)
| | - Wen-Dien Chang
- Department of Sport Performance, National Taiwan University of Sport, Taichung 404, Taiwan;
| | - Chih-Ho Lai
- Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
- Department of Pediatrics, Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Linkou 333, Taiwan
- Department of Microbiology, School of Medicine, China Medical University, Taichung 406, Taiwan
- Department of Nursing, Asia University, Taichung 413, Taiwan
- Correspondence: (C.-H.L.); (C.-M.C.)
| | - Chuan-Mu Chen
- Department of Life Sciences, Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan;
- The iEGG and Animal Biotechnology Center, Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan
- Correspondence: (C.-H.L.); (C.-M.C.)
| |
Collapse
|
22
|
Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, Yu D, Hung MC. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun 2021; 12:832. [PMID: 33547304 PMCID: PMC7864927 DOI: 10.1038/s41467-021-21099-2] [Citation(s) in RCA: 215] [Impact Index Per Article: 71.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2020] [Accepted: 01/07/2021] [Indexed: 01/30/2023] Open
Abstract
The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion and immunotherapy efficacy; however, the molecular mechanism is unclear. Here we show that PD-1 contributes to the persistence of PD-1+TIM-3+ T cells by binding to the TIM-3 ligand galectin-9 (Gal-9) and attenuates Gal-9/TIM-3-induced cell death. Anti-Gal-9 therapy selectively expands intratumoral TIM-3+ cytotoxic CD8 T cells and immunosuppressive regulatory T cells (Treg cells). The combination of anti-Gal-9 and an agonistic antibody to the co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptor-related protein) that depletes Treg cells induces synergistic antitumor activity. Gal-9 expression and secretion are promoted by interferon β and γ, and high Gal-9 expression correlates with poor prognosis in multiple human cancers. Our work uncovers a function for PD-1 in exhausted T cell survival and suggests Gal-9 as a promising target for immunotherapy.
Collapse
MESH Headings
- Adenocarcinoma/genetics
- Adenocarcinoma/immunology
- Adenocarcinoma/mortality
- Adenocarcinoma/therapy
- Animals
- Antibodies/pharmacology
- Antineoplastic Agents, Immunological/pharmacology
- Colonic Neoplasms/genetics
- Colonic Neoplasms/immunology
- Colonic Neoplasms/mortality
- Colonic Neoplasms/therapy
- Galectins/antagonists & inhibitors
- Galectins/genetics
- Galectins/immunology
- Gene Expression Regulation, Neoplastic/immunology
- Glucocorticoid-Induced TNFR-Related Protein/agonists
- Glucocorticoid-Induced TNFR-Related Protein/genetics
- Glucocorticoid-Induced TNFR-Related Protein/immunology
- Hepatitis A Virus Cellular Receptor 2/genetics
- Hepatitis A Virus Cellular Receptor 2/immunology
- Humans
- Immunotherapy/methods
- Jurkat Cells
- Melanoma, Experimental/genetics
- Melanoma, Experimental/immunology
- Melanoma, Experimental/mortality
- Melanoma, Experimental/therapy
- Mice
- Mice, Inbred BALB C
- Programmed Cell Death 1 Receptor/genetics
- Programmed Cell Death 1 Receptor/immunology
- Protein Binding
- Signal Transduction
- Skin Neoplasms/genetics
- Skin Neoplasms/immunology
- Skin Neoplasms/mortality
- Skin Neoplasms/therapy
- Survival Analysis
- T-Lymphocytes, Cytotoxic/drug effects
- T-Lymphocytes, Cytotoxic/immunology
- T-Lymphocytes, Cytotoxic/pathology
- T-Lymphocytes, Regulatory/drug effects
- T-Lymphocytes, Regulatory/immunology
- T-Lymphocytes, Regulatory/pathology
Collapse
Affiliation(s)
- Riyao Yang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
| | - Linlin Sun
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China
| | - Ching-Fei Li
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yu-Han Wang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Jun Yao
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Hui Li
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China
| | - Meisi Yan
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Pathology, Harbin Medical University, Harbin, China
| | - Wei-Chao Chang
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Jung-Mao Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Jong-Ho Cha
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Biomedical Sciences, College of Medicine, Inha University, Incheon, Korea
| | - Jennifer L Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Cheng-Wei Chou
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
- Division of Hematology/Medical Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
| | - Xian Sun
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Department of Medical Oncology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China
| | - Yalan Deng
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Chao-Kai Chou
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Dihua Yu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Mien-Chie Hung
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan.
| |
Collapse
|
23
|
Chang WC, Westbrook A, Strauss GP, Chu AOK, Chong CSY, Siu CMW, Chan SKW, Lee EHM, Hui CLM, Suen YM, Lo TL, Chen EYH. Abnormal cognitive effort allocation and its association with amotivation in first-episode psychosis. Psychol Med 2020; 50:2599-2609. [PMID: 31576787 DOI: 10.1017/s0033291719002769] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
BACKGROUND Abnormal effort-based decision-making represents a potential mechanism underlying motivational deficits (amotivation) in psychotic disorders. Previous research identified effort allocation impairment in chronic schizophrenia and focused mostly on physical effort modality. No study has investigated cognitive effort allocation in first-episode psychosis (FEP). METHOD Cognitive effort allocation was examined in 40 FEP patients and 44 demographically-matched healthy controls, using Cognitive Effort-Discounting (COGED) paradigm which quantified participants' willingness to expend cognitive effort in terms of explicit, continuous discounting of monetary rewards based on parametrically-varied cognitive demands (levels N of N-back task). Relationship between reward-discounting and amotivation was investigated. Group differences in reward-magnitude and effort-cost sensitivity, and differential associations of these sensitivity indices with amotivation were explored. RESULTS Patients displayed significantly greater reward-discounting than controls. In particular, such discounting was most pronounced in patients with high levels of amotivation even when N-back performance and reward base amount were taken into consideration. Moreover, patients exhibited reduced reward-benefit sensitivity and effort-cost sensitivity relative to controls, and that decreased sensitivity to reward-benefit but not effort-cost was correlated with diminished motivation. Reward-discounting and sensitivity indices were generally unrelated to other symptom dimensions, antipsychotic dose and cognitive deficits. CONCLUSION This study provides the first evidence of cognitive effort-based decision-making impairment in FEP, and indicates that decreased effort expenditure is associated with amotivation. Our findings further suggest that abnormal effort allocation and amotivation might primarily be related to blunted reward valuation. Prospective research is required to clarify the utility of effort-based measures in predicting amotivation and functional outcome in FEP.
Collapse
Affiliation(s)
- W C Chang
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong
| | - A Westbrook
- Donders Institute for Brain, Cognition and Behavior, Radboud University, Nijmegen 6525 EN, The Netherlands
- Department of Cognitive, Linguistics, and Psychological Sciences, Brown University, Providence, RI02906, USA
| | - G P Strauss
- Department of Psychology, University of Georgia, Athens, GA30602, USA
| | - A O K Chu
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong
| | - C S Y Chong
- Department of Psychiatry, Kwai Chung Hospital, Hong Kong
| | - C M W Siu
- Department of Psychiatry, Kwai Chung Hospital, Hong Kong
| | - S K W Chan
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong
| | - E H M Lee
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong
| | - C L M Hui
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong
| | - Y M Suen
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong
| | - T L Lo
- Department of Psychiatry, Kwai Chung Hospital, Hong Kong
| | - E Y H Chen
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Pok Fu Lam, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong
| |
Collapse
|
24
|
Hui CLM, Lam BST, Lee EHM, Chan SKW, Chang WC, Suen YN, Chen EYH. Perspective on medication decisions following remission from first-episode psychosis. Schizophr Res 2020; 225:82-89. [PMID: 32115314 DOI: 10.1016/j.schres.2020.02.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/03/2020] [Revised: 02/13/2020] [Accepted: 02/15/2020] [Indexed: 10/24/2022]
Abstract
While antipsychotics (APs) could provide rapid relief of positive symptoms in psychotic disorders, their usage is often associated with side effects, stigma and inconveniences. For these and other reasons, many psychosis patients, particularly those of first-episode psychosis (FEP) in remission, wish to discontinue maintenance treatment. The current review aims to discuss the strategies of AP treatment following remission from FEP, with particular emphasis on the evaluation of outcomes following AP discontinuation. Upon review of relevant literature, three potential strategies are put forth for treatment-responsive, remitted FEP patients: a) life-long maintenance treatment, b) AP discontinuation during second year of treatment, or c) AP discontinuation after three years of treatment. In theory, the first strategy presents the safest option for maximal symptom control. However, a rigorous RCT indicates that if AP discontinuation is to be attempted, the third strategy best prevents poor long-term clinical outcomes. Further data is needed to address the costs and benefits of each treatment strategy, compare AP-free patients with those on different types of APs, as well as explore even longer-term outcomes.
Collapse
Affiliation(s)
- Christy L M Hui
- Department of Psychiatry, University of Hong Kong, Hong Kong, China.
| | - Bertha S T Lam
- Department of Psychiatry, University of Hong Kong, Hong Kong, China
| | - Edwin H M Lee
- Department of Psychiatry, University of Hong Kong, Hong Kong, China
| | - Sherry K W Chan
- Department of Psychiatry, University of Hong Kong, Hong Kong, China; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong, China
| | - W C Chang
- Department of Psychiatry, University of Hong Kong, Hong Kong, China; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong, China
| | - Y N Suen
- Department of Psychiatry, University of Hong Kong, Hong Kong, China
| | - Eric Y H Chen
- Department of Psychiatry, University of Hong Kong, Hong Kong, China; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong, China
| |
Collapse
|
25
|
Chang WC, Wong CSM, Or PCF, Chu AOK, Hui CLM, Chan SKW, Lee EMH, Suen YN, Chen EYH. Inter-relationships among psychopathology, premorbid adjustment, cognition and psychosocial functioning in first-episode psychosis: a network analysis approach. Psychol Med 2020; 50:2019-2027. [PMID: 31451127 DOI: 10.1017/s0033291719002113] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND Better understanding of interplay among symptoms, cognition and functioning in first-episode psychosis (FEP) is crucial to promoting functional recovery. Network analysis is a promising data-driven approach to elucidating complex interactions among psychopathological variables in psychosis, but has not been applied in FEP. METHOD This study employed network analysis to examine inter-relationships among a wide array of variables encompassing psychopathology, premorbid and onset characteristics, cognition, subjective quality-of-life and psychosocial functioning in 323 adult FEP patients in Hong Kong. Graphical Least Absolute Shrinkage and Selection Operator (LASSO) combined with extended Bayesian information criterion (BIC) model selection was used for network construction. Importance of individual nodes in a generated network was quantified by centrality analyses. RESULTS Our results showed that amotivation played the most central role and had the strongest associations with other variables in the network, as indexed by node strength. Amotivation and diminished expression displayed differential relationships with other nodes, supporting the validity of two-factor negative symptom structure. Psychosocial functioning was most strongly connected with amotivation and was weakly linked to several other variables. Within cognitive domain, digit span demonstrated the highest centrality and was connected with most of the other cognitive variables. Exploratory analysis revealed no significant gender differences in network structure and global strength. CONCLUSION Our results suggest the pivotal role of amotivation in psychopathology network of FEP and indicate its critical association with psychosocial functioning. Further research is required to verify the clinical significance of diminished motivation on functional outcome in the early course of psychotic illness.
Collapse
Affiliation(s)
- W C Chang
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, Hong Kong
| | - C S M Wong
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
| | - P C F Or
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
| | - A O K Chu
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
| | - C L M Hui
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
| | - S K W Chan
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, Hong Kong
| | - E M H Lee
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
| | - Y N Suen
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
| | - E Y H Chen
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong, Hong Kong
| |
Collapse
|
26
|
Lin CC, Huang YK, Cho CF, Lin YS, Lo CC, Kuo TT, Tseng GC, Cheng WC, Chang WC, Hsiao TH, Lai LC, Shih JY, Liu YH, Chao KC, Hsu JL, Lee PC, Sun X, Hung MC, Sher YP. Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. Theranostics 2020; 10:10925-10939. [PMID: 33042262 PMCID: PMC7532684 DOI: 10.7150/thno.49425] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2020] [Accepted: 08/18/2020] [Indexed: 02/06/2023] Open
Abstract
Rationale: Brain metastasis in patients with lung cancer is life-threatening. However, the molecular mechanism for this catastrophic disease remains elusive, and few druggable targets are available. Therefore, this study aimed to identify and characterize proteins that could be used as therapeutic targets. Methods: Proteomic analyses were conducted to identify differentially expressed membrane proteins between brain metastatic lung cancer cells and primary lung cancer cells. A neuronal growth-associated protein, brain acid soluble protein 1 (BASP1), was chosen for further investigation. The clinical relevance of BASP1 in lung adenocarcinoma was first assessed. Tyrosine kinase activity assays and in vitro and in vivo functional assays were conducted to explore the oncogenic mechanisms of BASP1. Results: The protein levels of BASP1 were positively associated with tumor progression and poor prognosis in patients with lung adenocarcinoma. Membrane-bound BASP1 increased EGFR signaling and stabilized EGFR proteins by facilitating their escape from the ubiquitin-proteasome pathway. Reciprocally, activation of EGFR recruited more BASP1 to the plasma membrane, generating a positive feedback loop between BASP1 and EGFR. Moreover, the synergistic therapeutic effects of EGFR tyrosine kinase inhibitor and arsenic trioxide led to a reduction in the level of BASP1 protein observed in lung cancer cells with acquired resistance to EGFR inhibitors. Conclusions: The reciprocal interaction between BASP1 and EGFR facilitates EGFR signaling in brain metastatic lung cancer. Targeting the newly identified BASP1-EGFR interaction could open new venues for lung cancer treatment.
Collapse
|
27
|
Tomida N, Muramatsu N, Niiyama M, Ahn JK, Chang WC, Chen JY, Chu ML, Daté S, Gogami T, Goto H, Hamano H, Hashimoto T, He QH, Hicks K, Hiraiwa T, Honda Y, Hotta T, Ikuno H, Inoue Y, Ishikawa T, Jaegle I, Jo JM, Kasamatsu Y, Katsuragawa H, Kido S, Kon Y, Maruyama T, Masumoto S, Matsumura Y, Miyabe M, Mizutani K, Nagahiro H, Nakamura T, Nakano T, Nam T, Ngan TNT, Nozawa Y, Ohashi Y, Ohnishi H, Ohta T, Ozawa K, Rangacharyulu C, Ryu SY, Sada Y, Sasagawa M, Shibukawa T, Shimizu H, Shirai R, Shiraishi K, Strokovsky EA, Sugaya Y, Sumihama M, Suzuki S, Tanaka S, Tokiyasu A, Tsuchikawa Y, Ueda T, Yamazaki H, Yamazaki R, Yanai Y, Yorita T, Yoshida C, Yosoi M. Search for η^{'} Bound Nuclei in the ^{12}C(γ,p) Reaction with Simultaneous Detection of Decay Products. Phys Rev Lett 2020; 124:202501. [PMID: 32501086 DOI: 10.1103/physrevlett.124.202501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Revised: 02/11/2020] [Accepted: 04/30/2020] [Indexed: 06/11/2023]
Abstract
We measured missing mass spectrum of the ^{12}C(γ,p) reaction for the first time in coincidence with potential decay products from η^{'} bound nuclei. We tagged an (η+p) pair associated with the η^{'}N→ηN process in a nucleus. After applying kinematical selections to reduce backgrounds, no signal events were observed in the bound-state region. An upper limit of the signal cross section in the opening angle cosθ_{lab}^{ηp}<-0.9 was obtained to be 2.2 nb/sr at the 90% confidence level. It is compared with theoretical cross sections, whose normalization ambiguity is suppressed by measuring a quasifree η^{'} production rate. Our results indicate a small branching fraction of the η^{'}N→ηN process and/or a shallow η^{'}-nucleus potential.
Collapse
Affiliation(s)
- N Tomida
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - N Muramatsu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - M Niiyama
- Department of Physics, Kyoto Sangyo University, Kyoto 603-8555, Japan
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - W C Chang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - J Y Chen
- National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - M L Chu
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - S Daté
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Japan Synchrotron Radiation Research Institute (SPring-8), Sayo, Hyogo 679-5198, Japan
| | - T Gogami
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Goto
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Hamano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Hashimoto
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Q H He
- Department of Nuclear Science & Engineering, College of Material Science and Technology, Nanjing University of Aeronautics and Astronautics, Nanjing 210016, China
| | - K Hicks
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - T Hiraiwa
- RIKEN SPring-8 Center, Sayo, Hyogo 679-5148, Japan
| | - Y Honda
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Hotta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Ikuno
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Inoue
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Ishikawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - I Jaegle
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - J M Jo
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - Y Kasamatsu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Katsuragawa
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S Kido
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Kon
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Institute for Radiation Sciences, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Maruyama
- College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa 252-8510, Japan
| | - S Masumoto
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - Y Matsumura
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Miyabe
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - K Mizutani
- Thomas Jefferson National Accelerator Facility, Newport News, Virginia 23606, USA
| | - H Nagahiro
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Department of Physics, Nara Women's University, Nara 630-8506, Japan
| | - T Nakamura
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - T Nakano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Nam
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T N T Ngan
- Nuclear Physics Department, University of Science, Vietnam National University, Ho Chi Minh City 72711, Vietnam
| | - Y Nozawa
- Department of Radiology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - Y Ohashi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Ohnishi
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Ohta
- Department of Radiology, The University of Tokyo Hospital, Tokyo 113-8655, Japan
| | - K Ozawa
- Institute of Particle and Nuclear Studies, High Energy Accelerator Research Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - C Rangacharyulu
- Department of Physics and Engineering Physics, University of Saskatchewan, Saskatoon SK S7N 5E2, Canada
| | - S Y Ryu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Sada
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - M Sasagawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Shibukawa
- Department of Physics, University of Tokyo, Tokyo 113-0033, Japan
| | - H Shimizu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - R Shirai
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - K Shiraishi
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - E A Strokovsky
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Laboratory of High Energy Physics, Joint Institute for Nuclear Research, Dubna, Moscow Region 142281, Russia
| | - Y Sugaya
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Sumihama
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - S Suzuki
- Japan Synchrotron Radiation Research Institute (SPring-8), Sayo, Hyogo 679-5198, Japan
| | - S Tanaka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - A Tokiyasu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Tsuchikawa
- J-PARC Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T Ueda
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - H Yamazaki
- Radiation Science Center, High Energy Accelerator Research Organization (KEK), Tokai, Ibaraki 319-1195, Japan
| | - R Yamazaki
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Yanai
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Yorita
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - C Yoshida
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - M Yosoi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| |
Collapse
|
28
|
Fan CC, Tsai ST, Lin CY, Chang LC, Yang JC, Chen GY, Sher YP, Wang SC, Hsiao M, Chang WC. EFHD2 contributes to non-small cell lung cancer cisplatin resistance by the activation of NOX4-ROS-ABCC1 axis. Redox Biol 2020; 34:101571. [PMID: 32446175 PMCID: PMC7243194 DOI: 10.1016/j.redox.2020.101571] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Revised: 04/30/2020] [Accepted: 05/08/2020] [Indexed: 12/20/2022] Open
Abstract
Recurrence and metastasis remain the major cause of cancer mortality. Even for early-stage lung cancer, adjuvant chemotherapy yields merely slight increase to patient survival. EF-hand domain-containing protein D2 (EFHD2) has recently been implicated in recurrence of patients with stage I lung adenocarcinoma. In this study, we investigated the correlation between EFHD2 and chemoresistance in non-small cell lung cancer (NSCLC). High expression of EFHD2 was significantly associated with poor overall survival of NSCLC patients with chemotherapy in in silica analysis. Ectopic EFHD2 overexpression increased cisplatin resistance, whereas EFHD2 knockdown improved chemoresponse. Mechanistically, EFHD2 induced the production of NADPH oxidase 4 (NOX4) and in turn the increase of intracellular reactive oxygen species (ROS), consequently activating membrane expression of the ATP-binding cassette subfamily C member 1 (ABCC1) for drug efflux. Non-steroidal anti-inflammatory drug (NSAID) ibuprofen suppressed EFHD2 expression by leading to the proteasomal and lysosomal degradation of EFHD2 through a cyclooxygenase (COX)-independent mechanism. Combining ibuprofen with cisplatin enhanced antitumor responsiveness in a murine xenograft model in comparison with the individual treatment. In conclusion, we demonstrate that EFHD2 promotes chemoresistance through the NOX4-ROS-ABCC1 axis and therefore developing EFHD2-targeting strategies may offer a new avenue to improve adjuvant chemotherapy of lung cancer. EFHD2 increases resistance of lung cancer to cisplatin. EFHD2 enhances the NOX4-ROS-ABCC1signalingfor cisplatin efflux. Ibuprofen suppresses EFHD2 through both proteasomal and lysosomal degradationmechanisms
Collapse
Affiliation(s)
- Chi-Chen Fan
- Department of Superintendent Office, Mackay Memorial Hospital, Taipei, Taiwan; Department of Medical Laboratory Science and Biotechnology, Yuanpei University, Hsinchu, Taiwan
| | - Sheng-Ta Tsai
- Genomics Research Center, Academia Sinica, Taipei, Taiwan
| | - Chen-Yuan Lin
- Department of Hematology and Oncology, China Medical University Hospital, Taichung, Taiwan; School of Pharmacy, China Medical University, Taichung, Taiwan
| | - Ling-Chu Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Department of Biological Science and Technology, China Medical University, Taichung, Taiwan
| | - Juan-Cheng Yang
- Department of Superintendent Office, Mackay Memorial Hospital, Taipei, Taiwan; Department of Medical Laboratory Science and Biotechnology, Yuanpei University, Hsinchu, Taiwan; Department of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung, Taiwan; Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung, Taiwan
| | - Guan-Yu Chen
- Chinese Medicine Research and Development Center, China Medical University Hospital, Taichung, Taiwan
| | - Yuh-Pyng Sher
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Chinese Medicine Research Center, China Medical University, Taichung, Taiwan; Research Center for Chinese Herbal Medicine, China Medical University, Taichung, Taiwan
| | - Shao-Chun Wang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan; Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA; Department of Biotechnology, Asia University, Taichung, Taiwan
| | - Michael Hsiao
- Genomics Research Center, Academia Sinica, Taipei, Taiwan; Department of Biochemistry, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan.
| |
Collapse
|
29
|
Abstract
Objective: To obtain biomarkers of allergic rhinitis (AR) by performing bioinformatics analysis on gene chips related to allergic rhinitis in the Gene Expression Database (GEO). Methods: From June 2018 to December 2019, we downloaded data (GSE46171) involving 3 control individuals and 6 AR patients from the publicallyavailable Gene Expression Omnibus database (GEO,http://www.ncbi.nlm.nih.gov/geo), and differentially expressed genes (DEGs) were screened between AR and normal tissues by using the GEO2R online tool comprehensively. Then, we used the bioinformatics methods, including Gene Ontology (GO) analysis and Kyoto Encyclopedia of Gene, Genome (KEGG) pathway analysis and protein-protein interaction (PPI) network construction to identify key genes in AR. In the same period, the inferior turbinate mucosa tissues of 15 AR patients and 15 healthy controls were collected during operationinthe Department of Otolaryngology Head and Neck Surgery of the People 's Hospital of Wuhan Universityto further verify important genes and pathways and perform real-time quantitative PCR.SPSS9.0 statistical software was used for statistical analysis. Results: Two hundred and seventeen DEGs genes were selected, of which 112 were down-regulated genes and 105 were up-regulated genes. Among them, the five up-regulated genes with the most significant differences were KLK7, TMPRSS11A, SPRR2C, TPSAB1, and TXLNGY; the five down-regulated genes with the most significant differences were: XIST, CTAG1A, PRB1, CXCL11 and PRB2. By constructing a PPI network among 217 DEGs, the 15 hub genes obtained were IFIH1, CCR2, CD80, TLR7, EIF1AY, DDX3Y, RSAD2, RPS4Y2, RPS4Y1, XAF1, KDM5D, ZFY, NLGN4Y, IFIT5 and DDX60L, these Genes were at a hub in a gene network. We collected inferior turbinate mucosa tissue during surgery,and these 15 genes were verified, and the expressions of IFIH1, CCR2, CD80, TLR7, RSAD2, XAF1, IFIT5 and DDX60L were reduced, wherea the expressions of EIF1AY, DDX3Y, RPS4Y2, RPS4Y1, KDM5D, ZFY and NLGN4Y were increased, differences were statistically significant (all P<0.05). Conclusions: The study finds 217 genes closely related to allergic rhinitis and obtains 15 hub genes through the PPI network. These genes may be involved in the pathogenesis of allergic rhinitis and are expected to become new biomarkers for allergic rhinitis.
Collapse
Affiliation(s)
- W C Chang
- Department of Otorhinolaryngology Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
| | - Y Xu
- Department of Otorhinolaryngology Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China; Research Institute of Otorhinolaryngology Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China
| |
Collapse
|
30
|
Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Hsu J, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie C, McCoy A, Litton J, Mittendorf E, Moulder S, Symmans W, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Abstract A16: Metformin is a potential nontoxic adjuvant to enhance the efficacy of non-PDL1/PD-1 targeting immune therapies. Cancer Immunol Res 2020. [DOI: 10.1158/2326-6074.tumimm18-a16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Investigations into various immunotherapies combined with conventional anticancer drugs are ongoing to increase therapeutic efficacy. However, combination therapy generally increases the risk of side effects. To achieve high efficacy with minimal side effects, nontoxic adjuvants should be identified and appropriate combinations should be designed based on the functional mechanism. In this regard, metformin can be an attractive candidate for immunotherapeutic adjuvants. Metformin is a widely used oral medication for type 2 diabetes (T2D) and has been recognized as a safe and well-tolerated drug through several decades of clinical experience. Interestingly, metformin also exhibits antitumor effects as several case-control studies for T2D patients indicated that metformin reduces the incidence of various cancer types. However, the functions and the detailed mechanism of metformin related to cancer immunity are not fully understood. In this study, we investigated the antitumor effects of metformin in relation to cancer immunity in the tumor microenvironment. Our data showed that AMPK activated by metformin decreases the expression of PD-L1 in the cancer cells, blocking PD-L1’s ability to aid cancer cells in escaping immune surveillance. This is caused by the mechanism in which phosphorylation of PD-L1 at S195 induces an abnormal glycan structure that leads to endoplasmic reticulum-associated degradation. In addition, we have obtained human breast tumor tissues from a previous clinical trial investigating metformin as treatment for breast cancer patients. The data from human tumor tissues also provided strong support to our current conclusion, namely AMPK activated by metformin reduces the level of PD-L1. On the basis of these results, we validated the possibility of metformin as an adjuvant to boost the efficacy of previous immunotherapy without toxicity. Our findings suggest that metformin has strong potential to be used as an adjuvant for immunotherapy. Metformin is expected to have synergistic effect with various non-PDL1/PD-1 targeting immune therapies without additional toxicity.
Citation Format: Jong-Ho Cha, Wen-Hao Yang, Weiya Xia, Yongkun Wei, Li-Chuan Chan, Seung-Oe Lim, Chia-Wei Li, Jennifer Hsu, Hung-Ling Wang, Chu-Wei Kuo, Wei-Chao Chang, Sirwan Hadad, Colin Purdie, Aaron McCoy, Jennifer Litton, Elizabeth Mittendorf, Stacy Moulder, William Symmans, Alastair M Thompson, Helen Piwnica-Worms, Chung-Hsuan Chen, Kay-Hooi Khoo, Mien-Chie Hung. Metformin is a potential nontoxic adjuvant to enhance the efficacy of non-PDL1/PD-1 targeting immune therapies [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2018 Nov 27-30; Miami Beach, FL. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(4 Suppl):Abstract nr A16.
Collapse
Affiliation(s)
- Jong-Ho Cha
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Wen-Hao Yang
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Weiya Xia
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Yongkun Wei
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Li-Chuan Chan
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Seung-Oe Lim
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Chia-Wei Li
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Jennifer Hsu
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Hung-Ling Wang
- 2Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan,
| | - Chu-Wei Kuo
- 3Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei, Taiwan,
| | - Wei-Chao Chang
- 4Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, Taipei, Taiwan,
| | - Sirwan Hadad
- 5Department of Surgery, University of Sheffield, Western Bank, Sheffield, United Kingdom,
| | - Colin Purdie
- 6Department of Pathology, Ninewells Hospital and Medical School, Dundee, United Kingdom,
| | - Aaron McCoy
- 7Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Jennifer Litton
- 8Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Houston, TX,
| | - Elizabeth Mittendorf
- 9Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Stacy Moulder
- 8Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Houston, TX,
| | - William Symmans
- 10Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Alastair M Thompson
- 9Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | - Helen Piwnica-Worms
- 7Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| | | | - Kay-Hooi Khoo
- 12Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan
| | - Mien-Chie Hung
- 1Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX,
| |
Collapse
|
31
|
Lao KSJ, Wong AYS, Wong ICK, Besag FMC, Chang WC, Lee EHM, Chen EYH, Blais JE, Chan EW. Mortality Risk Associated with Haloperidol Use Compared with Other Antipsychotics: An 11-Year Population-Based Propensity-Score-Matched Cohort Study. CNS Drugs 2020; 34:197-206. [PMID: 31916101 DOI: 10.1007/s40263-019-00693-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
BACKGROUND Haloperidol remains a frequently prescribed first-generation antipsychotic. However, haloperidol-associated mortality risk by all causes, cardiovascular disease (CVD), and pneumonia compared with other antipsychotics is unknown. OBJECTIVE This study investigated the mortality risk associated with long-term haloperidol treatment versus that with other antipsychotics. METHODS We identified incident antipsychotic users from 2004 to 2014 in the Clinical Data Analysis and Reporting System (CDARS), a population-based clinical database managed by the Hong Kong Hospital Authority. We included patients who were aged ≥ 18 and received antipsychotics for any indication apart from terminal illnesses or management of acute behavioural disturbance. Patients on haloperidol and other antipsychotic agents (risperidone, quetiapine, olanzapine, chlorpromazine, aripiprazole, sulpiride, amisulpride, or trifluoperazine) were matched by propensity score. Hazard ratios (HRs) for all-cause mortality and death due to CVD and pneumonia were estimated with 95% confidence intervals (CIs) using a Cox proportional hazards model. RESULTS In total, 136,593 users of antipsychotics were included. During a mean follow-up of 3.2 years, the incidence of all-cause mortality ranged from 186.8/1000 person-years for haloperidol to 10.4/1000 person-years for trifluoperazine. The risk of all-cause mortality was lower with non-haloperidol antipsychotics than with haloperidol, with HRs ranging from 0.68 (95% CI 0.64-0.72 [chlorpromazine]) to 0.43 (95% CI 0.36-0.53 [trifluoperazine]). Risperidone, quetiapine, sulpiride, chlorpromazine, aripiprazole, and trifluoperazine were associated with a significantly lower risk of pneumonia-related mortality. A significantly lower risk of CVD mortality was observed for risperidone, sulpiride, chlorpromazine, and quetiapine. CONCLUSION Haloperidol was associated with increased overall mortality when compared with other antipsychotics in long-term follow-up. Treatment with haloperidol should be carefully considered, especially in older patients and patients at risk of CVD or pneumonia, since the risk of death appears to be lower with non-haloperidol agents.
Collapse
Affiliation(s)
- Kim S J Lao
- Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Office 02-08, 2/F Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.,Global Medical Affairs, Merck Research Laboratories, MSD, Shanghai, China
| | - Angel Y S Wong
- Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK
| | - Ian C K Wong
- Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Office 02-08, 2/F Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.,Research Department of Practice and Policy, UCL School of Pharmacy, London, UK
| | - Frank M C Besag
- Research Department of Practice and Policy, UCL School of Pharmacy, London, UK.,East London NHS Foundation Trust, Bedfordshire, UK.,Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK
| | - W C Chang
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.,State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR, China
| | - Edwin H M Lee
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Eric Y H Chen
- Department of Psychiatry, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.,State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong SAR, China
| | - Joseph E Blais
- Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Office 02-08, 2/F Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China
| | - Esther W Chan
- Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Office 02-08, 2/F Laboratory Block, 21 Sassoon Road, Pokfulam, Hong Kong SAR, China.
| |
Collapse
|
32
|
Liu CW, Chang WC, Pan RH. P282 Elevated serum uric acid associated with both electrocardiographic and echocardiographic left ventricular hypertrophy independent of blood pressure in healthy individuals. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehz872.102] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
TSGH 108-11
Background
Elevated serum uric acid (SUA) is associated with cardiac fibrosis and hypertrophy. A growing body of evidence showed the positive correlation between hyperuricemia (HUA) and left ventricular hypertrophy (LVH), but most studies defined LVH by a single method such as electrocardiogram or echocardiogram; the former is generally used in massive screen but the latter take advantage of the accuracy of LVH.
Purpose
We conducted this study to concomitantly investigate the association between SUA and electrocardiographic and echocardiographic LVH.
Methods
We initially enrolled 17,913 healthy individuals, who routinely underwent an annual health exam at our hospital between 2016/1/1∼2016/12/31. Of them, 347 individuals received transthoracic echocardiography because of abnormal results in their electrocardiogram. Amplitudes of 12-lead electrocardiogram were artificially measured by a study assistant under the supervision and by artificial intelligence. HUA is defined as an SUA level of ≥7 mg/dl in men and ≥6 mg/dl in women. Electrocardiographic LVH is defined by the criteria of Cornel voltage and product and Sokolow-Lyon and the Minnesota Code ECG classification. Echocardiographic LVH is defined by LV mass index ≥115g/m² in men or ≥95g/m² in women.
Results
The HUA group (n = 233) vs. normouricemic group (n = 114) was older and predominant male with greater values of body mass index, systolic and diastolic blood pressure and laboratory biomarkers, including non-high density total cholesterol, fasting glucose impairment, creatinine clearance, and haemoglobin. The two groups had comparable lifestyle choices, including tobacco use, alcohol intake, and physical activities per week. The HUA group compared with the normouricemic group had greater values of S amplitude of V1 plus R amplitude of V5 (3031 ± 2055 uV vs. 2566 ± 1021 uV, P = 0.005), R amplitude in lead I plus S amplitude in lead III (842 ± 443 uV vs. 696 ± 386 uV, P = 0.002) and LV mass index (95 ± 23 g/m² vs. 85 ± 30 g/m², P = 0.001). The prevalence of electrocardiographic and echocardiographic LVH was greater in the HUA group than the normouricemic group (7.0% vs. 2.1%, P = 0.034 for electrocardiographic LVH and 15.8% vs. 7.7%, P = 0.025 for echocardiographic LVH). In multivariate logistic regression analyses, elevated SUA was associated with LVH after the confounders were fully adjusted (OR: 1.38, 95% CI: 1.07-1.77, P = 0.012 for electrocardiographic LVH and OR: 1.58, 95% CI 1.15-2.17, P = 0.004 for echocardiographic LVH).
Conclusion
Elevated SUA is independently associated with the prevalence of both electrocardiographic and echocardiographic LVH in healthy individuals from Taiwan. Future studies might evaluate urate-lowering effects on the regression of LVH.
Collapse
Affiliation(s)
- C W Liu
- Tri-service General Hospital, Songshan branch, Taipei, Taiwan
| | - W C Chang
- Tri-service General Hospital, Songshan branch, Taipei, Taiwan
| | - R H Pan
- National Yang Ming University, Taipei, Taiwan
| |
Collapse
|
33
|
Chen HY, Wang ML, Laurent B, Hsu CH, Chen MT, Lin LT, Shen J, Chang WC, Hsu J, Hung MC, Chen YW, Huang PI, Yang YP, Li CP, Ma HI, Chen CH, Lin WC, Chiou SH. Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2. Theranostics 2020; 10:201-217. [PMID: 31903115 PMCID: PMC6929620 DOI: 10.7150/thno.35895] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2019] [Accepted: 08/01/2019] [Indexed: 12/12/2022] Open
Abstract
Carcinomatous progression and recurrence are the main therapeutic challenges frequently faced by patients with refractory tumors. However, the underlined molecular mechanism remains obscure. Methods: We found Musashi-1 (MSI1) transported into cytosol under stress condition by confocal microscopy and cell fractionation. Argonaute 2 (AGO2) was then identified as a cytosolic binding partner of MSI1 by Mass Spectrametry, immunoprecipitation, and recombinant protein pull-down assay. We used RNA-IP to determine the MSI1/AGO2 associated regions on downstream target mRNAs. Finally, we overexpressed C-terminus of MSI1 to disrupt endogenous MSI1/AGO2 interaction and confirm it effects on tmor progression. Results: Malignant tumors exhibit elevated level of cytosolic Musashi-1 (MSI1), which translocates into cytosol in response to stress and promote tumor progression. Cytosolic MSI1 forms a complex with AGO2 and stabilize or destabilize its target mRNAs by respectively binding to their 3´ untranslated region or coding domain sequence. Both MSI1 translocation and MSI1/AGO2 binding are essential for promoting tumor progression. Blocking MSI1 shuttling by either chemical inhibition or point mutation attenuates the growth of GBM-xenografts in mice. Importantly, overexpression of the C-terminus of MSI1 disrupts endogenous MSI1/AGO2 interaction and effectively reduces stress-induced tumor progression. Conclusion: Our findings highlight novel molecular functions of MSI1 during stress-induced carcinomatous recurrence, and suggest a new therapeutic strategy for refractory malignancies by targeting MSI1 translocation and its interaction with AGOs.
Collapse
|
34
|
Tsai PH, Chien Y, Wang ML, Hsu CH, Laurent B, Chou SJ, Chang WC, Chien CS, Li HY, Lee HC, Huo TI, Hung JH, Chen CH, Chiou SH. Ash2l interacts with Oct4-stemness circuitry to promote super-enhancer-driven pluripotency network. Nucleic Acids Res 2019; 47:10115-10133. [PMID: 31555818 PMCID: PMC6821267 DOI: 10.1093/nar/gkz801] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 09/05/2019] [Accepted: 09/10/2019] [Indexed: 01/31/2023] Open
Abstract
Pluripotency and cell fates can be modulated through the regulation of super-enhancers; however, the underlying mechanisms are unclear. Here, we showed a novel mechanism in which Ash2l directly binds to super-enhancers of several stemness genes to regulate pluripotency and self-renewal in pluripotent stem cells. Ash2l recruits Oct4/Sox2/Nanog (OSN) to form Ash2l/OSN complex at the super-enhancers of Jarid2, Nanog, Sox2 and Oct4, and further drives enhancer activation, upregulation of stemness genes, and maintains the pluripotent circuitry. Ash2l knockdown abrogates the OSN recruitment to all super-enhancers and further hinders the enhancer activation. In addition, CRISPRi/dCas9-mediated blocking of Ash2l-binding motifs at these super-enhancers also prevents OSN recruitment and enhancer activation, validating that Ash2l directly binds to super-enhancers and initiates the pluripotency network. Transfection of Ash2l with W118A mutation to disrupt Ash2l–Oct4 interaction fails to rescue Ash2l-driven enhancer activation and pluripotent gene upregulation in Ash2l-depleted pluripotent stem cells. Together, our data demonstrated Ash2l formed an enhancer-bound Ash2l/OSN complex that can drive enhancer activation, govern pluripotency network and stemness circuitry.
Collapse
Affiliation(s)
- Ping-Hsing Tsai
- Department of Medical Research, Taipei VeteransGeneral Hospital, Taipei 11217, Taiwan.,Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan
| | - Yueh Chien
- Department of Medical Research, Taipei VeteransGeneral Hospital, Taipei 11217, Taiwan.,Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan
| | - Mong-Lien Wang
- Department of Medical Research, Taipei VeteransGeneral Hospital, Taipei 11217, Taiwan.,Institute of Food Safety and Health Risk Assessment, National Yang-Ming University, Taipei 11221, Taiwan.,Institute of Biochemistry and Molecular Biology, National Yang-Ming University, Taipei 11221, Taiwan.,School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
| | - Chih-Hung Hsu
- Department of Public Health, and Women's Hospital, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China
| | - Benoit Laurent
- Boston Children's Hospital and Harvard Medical School, Boston MA 02115, USA
| | - Shih-Jie Chou
- Department of Medical Research, Taipei VeteransGeneral Hospital, Taipei 11217, Taiwan.,Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.,School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, Taichung 40447, Taiwan
| | - Chian-Shiu Chien
- Department of Medical Research, Taipei VeteransGeneral Hospital, Taipei 11217, Taiwan.,Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan
| | - Hsin-Yang Li
- School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.,Department of Obstetrics and Gynecology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Hsin-Chen Lee
- Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.,School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan
| | - Teh-Ia Huo
- Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.,Section of Gastroenterology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan
| | - Jui-Hung Hung
- Institutes of Data Science and Engineering, and Department of computer science, National Chiao-Tung University, Hsinchu 30010, Taiwan
| | | | - Shih-Hwa Chiou
- Department of Medical Research, Taipei VeteransGeneral Hospital, Taipei 11217, Taiwan.,Institute of Pharmacology, National Yang-Ming University, Taipei 11221, Taiwan.,Institute of Food Safety and Health Risk Assessment, National Yang-Ming University, Taipei 11221, Taiwan.,School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.,Genomic Research Center, Academia Sinica, Taipei 11529, Taiwan.,Center for Intelligent Drug Systems and Smart Bio-devices (IDS2B), National Chiao-Tung University, Hsinchu 30010, Taiwan
| |
Collapse
|
35
|
Chiang SK, Chang WC, Chen SE, Chang LC. DOCK1 Regulates Growth and Motility through the RRP1B-Claudin-1 Pathway in Claudin-Low Breast Cancer Cells. Cancers (Basel) 2019; 11:cancers11111762. [PMID: 31717460 PMCID: PMC6896004 DOI: 10.3390/cancers11111762] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 10/30/2019] [Accepted: 11/07/2019] [Indexed: 01/08/2023] Open
Abstract
Dedicator of cytokinesis 1 (DOCK1) is a critical regulator of cancer metastasis. Claudins are transmembrane proteins that play a role in epithelial barrier integrity. Due to a loss or low expression of claudins (CLDN), the claudin-low type of triple-negative breast cancer (TNBC) is characterized by a mesenchymal-like phenotype with strong metastatic potential. In order to elucidate the mechanism of DOCK1 in cancer metastasis, we first analyzed the transcriptomic changes using a clinical database of human TNBC and found that the increase in DOCK1 expression was highly correlated with the poor survival rate of TNBC patients. Interference with DOCK1 expression by shRNA resulted in re-expression of claudin-1 in conjunction with significant inhibition of cell viability and motility of claudin-low breast cancer cells. Accordingly, overexpression of claudin-1 suppressed cell viability and migration. Genetic knockdown and pharmacological blockade of Rac1/Rac2 up-regulated claudin-1. DOCK1 knockdown also caused a decrease in DNA methyltransferase (DNMT) expression and an increase in claudin-1 transcript and promoter activity. Furthermore, RRP1B mediated DOCK1 depletion, which up-regulated claudin-1 expression, cell viability, and motility in claudin-low breast cancer cells. This study demonstrated that DOCK1 mediates growth and motility through down-regulated claudin-1 expression via the RRP1B–DNMT–claudin-1 pathway and that claudin-1 serves as an important effector in DOCK1-mediated cancer progression and metastasis in claudin-low breast cancer cells.
Collapse
Affiliation(s)
- Shih-Kai Chiang
- Department of Animal Science, National Chung Hsing University, Taichung 40227, Taiwan;
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, Taichung 40447, Taiwan;
| | - Shuen-Ei Chen
- Department of Animal Science, National Chung Hsing University, Taichung 40227, Taiwan;
- Innovation and Development Center of Sustainable Agriculture (IDCSA), National Chung Hsing University, Taichung 40227, Taiwan
- The iEGG and Animal Biotechnology Center, National Chung Hsing University, Taichung 40227, Taiwan
- Research Center for Sustainable Energy and Nanotechnology, National Chung Hsing University, Taichung 40227, Taiwan
- Correspondence: (S.-E.C.); (L.-C.C.); Tel.: 886-4-22870613 (ext. 227) (S.-E.C.); +886-4-22052121 (ext. 7913) (L.-C.C.)
| | - Ling-Chu Chang
- Chinese Medicinal Research and Development Center, China Medical University Hospital, Taichung 40447, Taiwan
- Department of Biological Science and Technology, China Medical University, Taichung 40402, Taiwan
- Correspondence: (S.-E.C.); (L.-C.C.); Tel.: 886-4-22870613 (ext. 227) (S.-E.C.); +886-4-22052121 (ext. 7913) (L.-C.C.)
| |
Collapse
|
36
|
Shih YH, Chen LY, Shieh TM, Chang WC, Wang WC. The differential expression of the salivary peptidome in radiotherapy-induced Xerostomia. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz343.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Hui CL, Honer WG, Lee EH, Chang WC, Chan SK, Chen ES, Pang EP, Lui SS, Chung DW, Yeung WS, Ng RM, Lo WT, Jones PB, Sham P, Chen EY. Predicting first-episode psychosis patients who will never relapse over 10 years. Psychol Med 2019; 49:2206-2214. [PMID: 30375301 DOI: 10.1017/s0033291718003070] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Although relapse in psychosis is common, a small proportion of patients will not relapse in the long term. We examined the proportion and predictors of patients who never relapsed in the 10 years following complete resolution of positive symptoms from their first psychotic episode. METHOD Patients who previously enrolled in a 12-month randomized controlled trial on medication discontinuation and relapse following first-episode psychosis (FEP) were followed up after 10 years. Relapse of positive symptoms was operationalized as a change from a Clinical Global Impression scale positive score of <3 for at least 3 consecutive months to a score of ⩾3 (mild or more severe). Baseline predictors included basic demographics, premorbid functioning, symptoms, functioning, and neurocognitive functioning. RESULTS Out of 178 first-episode patients, 37 (21%) never relapsed during the 10-year period. Univariate predictors (p ⩽ 0.1) of patients who never relapsed included a duration of untreated psychosis (DUP) ⩽30 days, diagnosed with non-schizophrenia spectrum disorders, having less severe negative symptoms, and performing better in logical memory immediate recall and verbal fluency tests. A multivariate logistic regression analysis further suggested that the absence of any relapsing episodes was significantly related to better short-term verbal memory, shorter DUP, and non-schizophrenia spectrum disorders. CONCLUSIONS Treatment delay and neurocognitive function are potentially modifiable predictors of good long-term prognosis in FEP. These predictors are informative as they can be incorporated into an optimum risk prediction model in the future, which would help with clinical decision making regarding maintenance treatment in FEP.
Collapse
Affiliation(s)
- Christy Lm Hui
- Department of Psychiatry, University of Hong Kong, Hong Kong
| | - William G Honer
- Department of Psychiatry, University of British Columbia, Vancouver, Canada
| | - Edwin Hm Lee
- Department of Psychiatry, University of Hong Kong, Hong Kong
| | - W C Chang
- Department of Psychiatry, University of Hong Kong, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong
| | - Sherry Kw Chan
- Department of Psychiatry, University of Hong Kong, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong
| | - Emily Sm Chen
- Department of Psychiatry, University of Hong Kong, Hong Kong
| | - Edwin Pf Pang
- Department of Psychiatry, United Christian Hospital, Hong Kong
| | - Simon Sy Lui
- Department of Psychiatry, Castle Peak Hospital, Hong Kong
| | | | - W S Yeung
- Department of Psychiatry, Pamela Youde Nethersole Eastern Hospital, Hong Kong
| | - Roger Mk Ng
- Department of Psychiatry, Kowloon Hospital, Hong Kong
| | - William Tl Lo
- Department of Psychiatry, Kwai Chung Hospital, Hong Kong
| | - Peter B Jones
- Department of Psychiatry, University of Cambridge, Cambridge, England
| | - Pak Sham
- Department of Psychiatry, University of Hong Kong, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong
- Centre for Genomic Sciences, University of Hong Kong, Hong Kong
| | - Eric Yh Chen
- Department of Psychiatry, University of Hong Kong, Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong
| |
Collapse
|
38
|
Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 2019; 129:3324-3338. [PMID: 31305264 DOI: 10.1172/jci126022] [Citation(s) in RCA: 182] [Impact Index Per Article: 36.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2018] [Accepted: 05/21/2019] [Indexed: 02/06/2023] Open
Abstract
Glycosylation of immune receptors and ligands, such as T cell receptor and coinhibitory molecules, regulates immune signaling activation and immune surveillance. However, how oncogenic signaling initiates glycosylation of coinhibitory molecules to induce immunosuppression remains unclear. Here we show that IL-6-activated JAK1 phosphorylates programmed death-ligand 1 (PD-L1) Tyr112, which recruits the endoplasmic reticulum-associated N-glycosyltransferase STT3A to catalyze PD-L1 glycosylation and maintain PD-L1 stability. Targeting of IL-6 by IL-6 antibody induced synergistic T cell killing effects when combined with anti-T cell immunoglobulin mucin-3 (anti-Tim-3) therapy in animal models. A positive correlation between IL-6 and PD-L1 expression was also observed in hepatocellular carcinoma patient tumor tissues. These results identify a mechanism regulating PD-L1 glycosylation initiation and suggest the combination of anti-IL-6 and anti-Tim-3 as an effective marker-guided therapeutic strategy.
Collapse
Affiliation(s)
- Li-Chuan Chan
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Chia-Wei Li
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Weiya Xia
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Jung-Mao Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Heng-Huan Lee
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Jong-Ho Cha
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Tumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University, Seoul, Korea
| | - Hung-Ling Wang
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Wen-Hao Yang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Er-Yen Yen
- Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Wei-Chao Chang
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Zhengyu Zha
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Seung-Oe Lim
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Yun-Ju Lai
- Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Chunxiao Liu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Jielin Liu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Qiongzhu Dong
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Department of General Surgery, Huashan Hospital and Cancer Metastasis Institute and Institutes of Biomedical Sciences, Fudan University, Shanghai, China
| | - Yi Yang
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Linlin Sun
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China
| | - Yongkun Wei
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Lei Nie
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Jennifer L Hsu
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan.,Department of Biotechnology, Asia University, Taichung, Taiwan
| | - Hui Li
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China
| | - Qinghai Ye
- Liver Cancer Institute, Zhongshan Hospital, Fudan University and Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai, China
| | - Manal M Hassan
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Hesham M Amin
- Department of Hematopathology, Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Ahmed O Kaseb
- Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
| | - Xin Lin
- Institute for Immunology, Tsinghua University School of Medicine, Beijing, China
| | - Shao-Chun Wang
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan
| | - Mien-Chie Hung
- Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.,Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas, USA.,Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan.,Department of Biotechnology, Asia University, Taichung, Taiwan
| |
Collapse
|
39
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Akimoto R, Al-Bataineh H, Alexander J, Alfred M, Al-Jamel A, Al-Ta'ani H, Angerami A, Aoki K, Apadula N, Aphecetche L, Aramaki Y, Armendariz R, Aronson SH, Asai J, Asano H, Aschenauer EC, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bagoly A, Bai M, Baksay G, Baksay L, Baldisseri A, Bannier B, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Bauer F, Baumann C, Baumgart S, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bhom JH, Bickley AA, Bjorndal MT, Blau DS, Boer M, Boissevain JG, Bok JS, Borel H, Boyle K, Brooks ML, Brown DS, Bryslawskyj J, Bucher D, Buesching H, Bumazhnov V, Bunce G, Burward-Hoy JM, Butsyk S, Camacho CM, Campbell S, Canoa Roman V, Caringi A, Castera P, Chai JS, Chang BS, Chang WC, Charvet JL, Chen CH, Chernichenko S, Chi CY, Chiba J, Chiu M, Choi IJ, Choi JB, Choi S, Choudhury RK, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cleven CR, Cobigo Y, Cole BA, Comets MP, Conesa Del Valle Z, Connors M, Constantin P, Csanád M, Csörgő T, Dahms T, Dairaku S, Danchev I, Danley TW, Das K, Datta A, Daugherity MS, David G, Dayananda MK, Deaton MB, Dehmelt K, Delagrange H, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Ding L, Dion A, Do JH, Donadelli M, D'Orazio L, Drachenberg JL, Drapier O, Drees A, Drees KA, Dubey AK, Durham JM, Durum A, Dutta D, Dzhordzhadze V, Edwards S, Efremenko YV, Egdemir J, Ellinghaus F, Emam WS, Engelmore T, Enokizono A, En'yo H, Espagnon B, Esumi S, Eyser KO, Fadem B, Fan W, Feege N, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Forestier B, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fung SY, Fusayasu T, Gadrat S, Gainey K, Gal C, Gallus P, Garg P, Garishvili A, Garishvili I, Gastineau F, Ge H, Germain M, Glenn A, Gong H, Gong X, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grim G, Grosse Perdekamp M, Gunji T, Guo L, Gustafsson HÅ, Hachiya T, Hadj Henni A, Haegemann C, Haggerty JS, Hagiwara MN, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Harada H, Hartouni EP, Haruna K, Harvey M, Hasegawa S, Haseler TOS, Hashimoto K, Haslum E, Hasuko K, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Heuser JM, Hiejima H, Hill JC, Hill K, Hobbs R, Hodges A, Hohlmann M, Hollis RS, Holmes M, Holzmann W, Homma K, Hong B, Horaguchi T, Hori Y, Hornback D, Hotvedt N, Huang J, Huang S, Hur MG, Ichihara T, Ichimiya R, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Inoue Y, Iordanova A, Isenhower D, Isenhower L, Ishihara M, Isobe T, Issah M, Isupov A, Ivanishchev D, Iwanaga Y, Jacak BV, Javani M, Ji Z, Jia J, Jiang X, Jin J, Jinnouchi O, Johnson BM, Jones T, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kaneta M, Kaneti S, Kang BH, Kang JH, Kang JS, Kanou H, Kapustinsky J, Karatsu K, Kasai M, Kawagishi T, Kawall D, Kawashima M, Kazantsev AV, Kelly S, Kempel T, Khachatryan V, Khanzadeev A, Kijima KM, Kikuchi J, Kim A, Kim BI, Kim C, Kim DH, Kim DJ, Kim E, Kim EJ, Kim HJ, Kim KB, Kim M, Kim SH, Kim YJ, Kim YK, Kim YS, Kincses D, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Kiyomichi A, Klatsky J, Klay J, Klein-Boesing C, Kleinjan D, Kline P, Kochenda L, Kochetkov V, Komatsu Y, Komkov B, Konno M, Koster J, Kotchetkov D, Kotov D, Kozlov A, Král A, Kravitz A, Krizek F, Kroon PJ, Kubart J, Kunde GJ, Kurgyis B, Kurihara N, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Le Bornec Y, Leckey S, Lee B, Lee DM, Lee J, Lee KB, Lee KS, Lee MK, Lee SH, Lee SR, Lee T, Leitch MJ, Leite MAL, Leitgab M, Lenzi B, Leung YH, Lewis B, Lewis NA, Li X, Li X, Li XH, Lichtenwalner P, Liebing P, Lim H, Lim SH, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Lökös S, Love B, Lynch D, Maguire CF, Majoros T, Makdisi YI, Makek M, Malakhov A, Malik MD, Manion A, Manko VI, Mannel E, Mao Y, Mašek L, Masui H, Masumoto S, Matathias F, McCain MC, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Means N, Mendoza M, Meredith B, Miake Y, Mibe T, Mignerey AC, Mihalik DE, Mikeš P, Miki K, Miller TE, Milov A, Mioduszewski S, Mishra DK, Mishra GC, Mishra M, Mitchell JT, Mitrovski M, Mitsuka G, Miyachi Y, Miyasaka S, Mohanty AK, Mohapatra S, Moon HJ, Moon T, Morino Y, Morreale A, Morrison DP, Morrow SI, Moss JM, Motschwiller S, Moukhanova TV, Mukhopadhyay D, Murakami T, Murata J, Mwai A, Nagae T, Nagamiya S, Nagashima K, Nagata Y, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nam S, Nattrass C, Nederlof A, Newby J, Nguyen M, Nihashi M, Niida T, Norman BE, Nouicer R, Novák T, Novitzky N, Nyanin AS, Nystrand J, Oakley C, O'Brien E, Oda SX, Ogilvie CA, Ohnishi H, Ojha ID, Oka M, Okada K, Omiwade OO, Onuki Y, Orjuela Koop JD, Osborn JD, Oskarsson A, Otterlund I, Ouchida M, Ozawa K, Pak R, Pal D, Palounek APT, Pantuev V, Papavassiliou V, Park BH, Park IH, Park J, Park S, Park SK, Park WJ, Pate SF, Patel L, Patel M, Pei H, Peng JC, Peng W, Pereira H, Perepelitsa DV, Peresedov V, Peressounko DY, PerezLara CE, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Radzevich PV, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reuter M, Reygers K, Reynolds D, Riabov V, Riabov Y, Richardson E, Richford D, Rinn T, Roach D, Roche G, Rolnick SD, Romana A, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rowan Z, Rukoyatkin P, Runchey J, Ružička P, Rykov VL, Ryu SS, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Sakata H, Sako H, Samsonov V, Sano M, Sano S, Sarsour M, Sato HD, Sato S, Sato T, Sawada S, Schmoll BK, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Sen A, Seto R, Sharma D, Shea TK, Shein I, Shevel A, Shibata TA, Shigaki K, Shimomura M, Shohjoh T, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Skoby MJ, Skutnik S, Slunečka M, Smith WC, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sullivan JP, Sun J, Sun Z, Sziklai J, Tabaru T, Takagi S, Takagui EM, Takahara A, Taketani A, Tanabe R, Tanaka KH, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Tennant E, Themann H, Thomas D, Thomas TL, Tieulent R, Todoroki T, Togawa M, Toia A, Tojo J, Tomášek L, Tomášek M, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Tsuji T, Tuli SK, Tydesjö H, Tyurin N, Ueda Y, Ujvari B, Vale C, Valle H, van Hecke HW, Vargyas M, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wagner M, Walker D, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Watanabe YS, Wei F, Wei R, Wessels J, White SN, Willis N, Winter D, Wolin S, Wong CP, Woody CL, Wright RM, Wysocki M, Xia B, Xie W, Xu C, Xu Q, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Yasin Z, Ying J, Yokkaichi S, Yoo JH, You Z, Young GR, Younus I, Yu H, Yushmanov IE, Zajc WA, Zaudtke O, Zelenski A, Zhang C, Zharko S, Zhou S, Zimamyi J, Zolin L, Zou L. Beam Energy and Centrality Dependence of Direct-Photon Emission from Ultrarelativistic Heavy-Ion Collisions. Phys Rev Lett 2019; 123:022301. [PMID: 31386493 DOI: 10.1103/physrevlett.123.022301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 04/27/2019] [Indexed: 06/10/2023]
Abstract
The PHENIX collaboration presents first measurements of low-momentum (0.4<p_{T}<3 GeV/c) direct-photon yields from Au+Au collisions at sqrt[s_{NN}]=39 and 62.4 GeV. For both beam energies the direct-photon yields are substantially enhanced with respect to expectations from prompt processes, similar to the yields observed in Au+Au collisions at sqrt[s_{NN}]=200. Analyzing the photon yield as a function of the experimental observable dN_{ch}/dη reveals that the low-momentum (>1 GeV/c) direct-photon yield dN_{γ}^{dir}/dη is a smooth function of dN_{ch}/dη and can be well described as proportional to (dN_{ch}/dη)^{α} with α≈1.25. This scaling behavior holds for a wide range of beam energies at the Relativistic Heavy Ion Collider and the Large Hadron Collider, for centrality selected samples, as well as for different A+A collision systems. At a given beam energy, the scaling also holds for high p_{T} (>5 GeV/c), but when results from different collision energies are compared, an additional sqrt[s_{NN}]-dependent multiplicative factor is needed to describe the integrated-direct-photon yield.
Collapse
Affiliation(s)
- A Adare
- University of Colorado, Boulder, Colorado 80309, USA
| | - S Afanasiev
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - C Aidala
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Department of Physics, University of Massachusetts, Amherst, Massachusetts 01003-9337, USA
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109-1040, USA
| | - N N Ajitanand
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - Y Akiba
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - R Akimoto
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - H Al-Bataineh
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - J Alexander
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - M Alfred
- Department of Physics and Astronomy, Howard University, Washington, DC 20059, USA
| | - A Al-Jamel
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - H Al-Ta'ani
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - A Angerami
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - K Aoki
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - N Apadula
- Iowa State University, Ames, Iowa 50011, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - L Aphecetche
- SUBATECH (Ecole des Mines de Nantes, CNRS-IN2P3, Université de Nantes), BP 20722-44307 Nantes, France
| | - Y Aramaki
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - R Armendariz
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - S H Aronson
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - J Asai
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - H Asano
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - E C Aschenauer
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - E T Atomssa
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - R Averbeck
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - T C Awes
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - B Azmoun
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - V Babintsev
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - A Bagoly
- ELTE, Eötvös Loránd University, H-1117 Budapest, Pázmány P. s. 1/A, Hungary
| | - M Bai
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - G Baksay
- Florida Institute of Technology, Melbourne, Florida 32901, USA
| | - L Baksay
- Florida Institute of Technology, Melbourne, Florida 32901, USA
| | - A Baldisseri
- Dapnia, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - B Bannier
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - K N Barish
- University of California-Riverside, Riverside, California 92521, USA
| | - P D Barnes
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - B Bassalleck
- University of New Mexico, Albuquerque, New Mexico 87131, USA
| | - A T Basye
- Abilene Christian University, Abilene, Texas 79699, USA
| | - S Bathe
- Baruch College, City University of New York, New York, New York 10010, USA
- University of California-Riverside, Riverside, California 92521, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S Batsouli
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - V Baublis
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
| | - F Bauer
- University of California-Riverside, Riverside, California 92521, USA
| | - C Baumann
- Institut für Kernphysik, University of Münster, D-48149 Münster, Germany
| | - S Baumgart
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - A Bazilevsky
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S Belikov
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Iowa State University, Ames, Iowa 50011, USA
| | - R Belmont
- University of Colorado, Boulder, Colorado 80309, USA
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - R Bennett
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - A Berdnikov
- Saint Petersburg State Polytechnic University, St. Petersburg 195251, Russia
| | - Y Berdnikov
- Saint Petersburg State Polytechnic University, St. Petersburg 195251, Russia
| | - J H Bhom
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - A A Bickley
- University of Colorado, Boulder, Colorado 80309, USA
| | - M T Bjorndal
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - D S Blau
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
- National Research Nuclear University, MEPhI, Moscow Engineering Physics Institute, Moscow 115409, Russia
| | - M Boer
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J G Boissevain
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J S Bok
- University of New Mexico, Albuquerque, New Mexico 87131, USA
- New Mexico State University, Las Cruces, New Mexico 88003, USA
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - H Borel
- Dapnia, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - K Boyle
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M L Brooks
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - D S Brown
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - J Bryslawskyj
- Baruch College, City University of New York, New York, New York 10010, USA
- University of California-Riverside, Riverside, California 92521, USA
| | - D Bucher
- Institut für Kernphysik, University of Münster, D-48149 Münster, Germany
| | - H Buesching
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - V Bumazhnov
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - G Bunce
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - J M Burward-Hoy
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S Butsyk
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- University of New Mexico, Albuquerque, New Mexico 87131, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - C M Camacho
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S Campbell
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - V Canoa Roman
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - A Caringi
- Muhlenberg College, Allentown, Pennsylvania 18104-5586, USA
| | - P Castera
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - J-S Chai
- KAERI, Cyclotron Application Laboratory, Seoul 34057, Korea
- Sungkyunkwan University, Suwon 440-746, Korea
| | - B S Chang
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - W C Chang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - J-L Charvet
- Dapnia, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - C-H Chen
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - S Chernichenko
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - C Y Chi
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - J Chiba
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | - M Chiu
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - I J Choi
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - J B Choi
- Chonbuk National University, Jeonju 561-756, Korea
| | - S Choi
- Department of Physics and Astronomy, Seoul National University, Seoul 151-742, Korea
| | - R K Choudhury
- Bhabha Atomic Research Centre, Bombay 400 085, India
| | - P Christiansen
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - T Chujo
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - P Chung
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - A Churyn
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - O Chvala
- University of California-Riverside, Riverside, California 92521, USA
| | - V Cianciolo
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - Z Citron
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
- Weizmann Institute, Rehovot 76100, Israel
| | - C R Cleven
- Georgia State University, Atlanta, Georgia 30303, USA
| | - Y Cobigo
- Dapnia, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - B A Cole
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - M P Comets
- IPN-Orsay, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, BP1, F-91406 Orsay, France
| | - Z Conesa Del Valle
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | - M Connors
- Georgia State University, Atlanta, Georgia 30303, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - P Constantin
- Iowa State University, Ames, Iowa 50011, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M Csanád
- ELTE, Eötvös Loránd University, H-1117 Budapest, Pázmány P. s. 1/A, Hungary
| | - T Csörgő
- Eszterházy Károly University, Károly Róbert Campus, H-3200 Gyöngyös, Mátrai út 36, Hungary
- Institute for Particle and Nuclear Physics, Wigner Research Centre for Physics, Hungarian Academy of Sciences (Wigner RCP, RMKI) H-1525 Budapest 114, POBox 49, Budapest, Hungary
| | - T Dahms
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - S Dairaku
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - I Danchev
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - T W Danley
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - K Das
- Florida State University, Tallahassee, Florida 32306, USA
| | - A Datta
- Department of Physics, University of Massachusetts, Amherst, Massachusetts 01003-9337, USA
| | | | - G David
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M K Dayananda
- Georgia State University, Atlanta, Georgia 30303, USA
| | - M B Deaton
- Abilene Christian University, Abilene, Texas 79699, USA
| | - K Dehmelt
- Florida Institute of Technology, Melbourne, Florida 32901, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - H Delagrange
- SUBATECH (Ecole des Mines de Nantes, CNRS-IN2P3, Université de Nantes), BP 20722-44307 Nantes, France
| | - A Denisov
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - D d'Enterria
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | - A Deshpande
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - E J Desmond
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | | | - O Dietzsch
- Universidade de São Paulo, Instituto de Física, Caixa Postal 66318, São Paulo CEP05315-970, Brazil
| | - L Ding
- Iowa State University, Ames, Iowa 50011, USA
| | - A Dion
- Iowa State University, Ames, Iowa 50011, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - J H Do
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - M Donadelli
- Universidade de São Paulo, Instituto de Física, Caixa Postal 66318, São Paulo CEP05315-970, Brazil
| | - L D'Orazio
- University of Maryland, College Park, Maryland 20742, USA
| | | | - O Drapier
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | - A Drees
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - K A Drees
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - A K Dubey
- Weizmann Institute, Rehovot 76100, Israel
| | - J M Durham
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - A Durum
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - D Dutta
- Bhabha Atomic Research Centre, Bombay 400 085, India
| | - V Dzhordzhadze
- University of California-Riverside, Riverside, California 92521, USA
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Edwards
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Florida State University, Tallahassee, Florida 32306, USA
| | - Y V Efremenko
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - J Egdemir
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - F Ellinghaus
- University of Colorado, Boulder, Colorado 80309, USA
| | - W S Emam
- University of California-Riverside, Riverside, California 92521, USA
| | - T Engelmore
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - A Enokizono
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Physics Department, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - H En'yo
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - B Espagnon
- IPN-Orsay, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, BP1, F-91406 Orsay, France
| | - S Esumi
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - K O Eyser
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- University of California-Riverside, Riverside, California 92521, USA
| | - B Fadem
- Muhlenberg College, Allentown, Pennsylvania 18104-5586, USA
| | - W Fan
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - N Feege
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - D E Fields
- University of New Mexico, Albuquerque, New Mexico 87131, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - M Finger
- Charles University, Ovocný trh 5, Praha 1, 116 36 Prague, Czech Republic
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - M Finger
- Charles University, Ovocný trh 5, Praha 1, 116 36 Prague, Czech Republic
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - F Fleuret
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | - S L Fokin
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
| | - B Forestier
- LPC, Université Blaise Pascal, CNRS-IN2P3, Clermont-Fd, 63177 Aubiere Cedex, France
| | - Z Fraenkel
- Weizmann Institute, Rehovot 76100, Israel
| | - J E Frantz
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - A Franz
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - A D Frawley
- Florida State University, Tallahassee, Florida 32306, USA
| | - K Fujiwara
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - Y Fukao
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - S-Y Fung
- University of California-Riverside, Riverside, California 92521, USA
| | - T Fusayasu
- Nagasaki Institute of Applied Science, Nagasaki-shi, Nagasaki 851-0193, Japan
| | - S Gadrat
- LPC, Université Blaise Pascal, CNRS-IN2P3, Clermont-Fd, 63177 Aubiere Cedex, France
| | - K Gainey
- Abilene Christian University, Abilene, Texas 79699, USA
| | - C Gal
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - P Gallus
- Czech Technical University, Zikova 4, 166 36 Prague 6, Czech Republic
| | - P Garg
- Department of Physics, Banaras Hindu University, Varanasi 221005, India
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - A Garishvili
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - I Garishvili
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - F Gastineau
- SUBATECH (Ecole des Mines de Nantes, CNRS-IN2P3, Université de Nantes), BP 20722-44307 Nantes, France
| | - H Ge
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M Germain
- SUBATECH (Ecole des Mines de Nantes, CNRS-IN2P3, Université de Nantes), BP 20722-44307 Nantes, France
| | - A Glenn
- University of Colorado, Boulder, Colorado 80309, USA
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - H Gong
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - X Gong
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - M Gonin
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | - J Gosset
- Dapnia, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - Y Goto
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - R Granier de Cassagnac
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | - N Grau
- Department of Physics, Augustana University, Sioux Falls, South Dakota 57197, USA
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Iowa State University, Ames, Iowa 50011, USA
| | - S V Greene
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - G Grim
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M Grosse Perdekamp
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - T Gunji
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - L Guo
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - H-Å Gustafsson
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - T Hachiya
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
- Nara Women's University, Kita-uoya Nishi-machi, Nara 630-8506, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - A Hadj Henni
- SUBATECH (Ecole des Mines de Nantes, CNRS-IN2P3, Université de Nantes), BP 20722-44307 Nantes, France
| | - C Haegemann
- University of New Mexico, Albuquerque, New Mexico 87131, USA
| | - J S Haggerty
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - M N Hagiwara
- Abilene Christian University, Abilene, Texas 79699, USA
| | - K I Hahn
- Ewha Womans University, Seoul 120-750, Korea
| | - H Hamagaki
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - J Hamblen
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - R Han
- Peking University, Beijing 100871, People's Republic of China
| | - J Hanks
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - H Harada
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - E P Hartouni
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K Haruna
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - M Harvey
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S Hasegawa
- Advanced Science Research Center, Japan Atomic Energy Agency, 2-4 Shirakata Shirane, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - T O S Haseler
- Georgia State University, Atlanta, Georgia 30303, USA
| | - K Hashimoto
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Physics Department, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - E Haslum
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - K Hasuko
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - R Hayano
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - X He
- Georgia State University, Atlanta, Georgia 30303, USA
| | - M Heffner
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T K Hemmick
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - T Hester
- University of California-Riverside, Riverside, California 92521, USA
| | - J M Heuser
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - H Hiejima
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - J C Hill
- Iowa State University, Ames, Iowa 50011, USA
| | - K Hill
- University of Colorado, Boulder, Colorado 80309, USA
| | - R Hobbs
- University of New Mexico, Albuquerque, New Mexico 87131, USA
| | - A Hodges
- Georgia State University, Atlanta, Georgia 30303, USA
| | - M Hohlmann
- Florida Institute of Technology, Melbourne, Florida 32901, USA
| | - R S Hollis
- University of California-Riverside, Riverside, California 92521, USA
| | - M Holmes
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - W Holzmann
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - K Homma
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - B Hong
- Korea University, Seoul 02841, Korea
| | - T Horaguchi
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro, Tokyo 152-8551, Japan
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - Y Hori
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - D Hornback
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - N Hotvedt
- Iowa State University, Ames, Iowa 50011, USA
| | - J Huang
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S Huang
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - M G Hur
- KAERI, Cyclotron Application Laboratory, Seoul 34057, Korea
| | - T Ichihara
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - R Ichimiya
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - H Iinuma
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - Y Ikeda
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - K Imai
- Advanced Science Research Center, Japan Atomic Energy Agency, 2-4 Shirakata Shirane, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - J Imrek
- Debrecen University, H-4010 Debrecen, Egyetem tér 1, Hungary
| | - M Inaba
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - Y Inoue
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Physics Department, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - A Iordanova
- University of California-Riverside, Riverside, California 92521, USA
| | - D Isenhower
- Abilene Christian University, Abilene, Texas 79699, USA
| | - L Isenhower
- Abilene Christian University, Abilene, Texas 79699, USA
| | - M Ishihara
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - T Isobe
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - M Issah
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - A Isupov
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - D Ivanishchev
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
| | - Y Iwanaga
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - B V Jacak
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M Javani
- Georgia State University, Atlanta, Georgia 30303, USA
| | - Z Ji
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - J Jia
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - X Jiang
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J Jin
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - O Jinnouchi
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - B M Johnson
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Georgia State University, Atlanta, Georgia 30303, USA
| | - T Jones
- Abilene Christian University, Abilene, Texas 79699, USA
| | - K S Joo
- Myongji University, Yongin, Kyonggido 449-728, Korea
| | - D Jouan
- IPN-Orsay, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, BP1, F-91406 Orsay, France
| | - D S Jumper
- Abilene Christian University, Abilene, Texas 79699, USA
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - F Kajihara
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - S Kametani
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Waseda University, Advanced Research Institute for Science and Engineering, 17 Kikui-cho, Shinjuku-ku, Tokyo 162-0044, Japan
| | - N Kamihara
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - J Kamin
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M Kaneta
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S Kaneti
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - B H Kang
- Hanyang University, Seoul 133-792, Korea
| | - J H Kang
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - J S Kang
- Hanyang University, Seoul 133-792, Korea
| | - H Kanou
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - J Kapustinsky
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - K Karatsu
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - M Kasai
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Physics Department, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - T Kawagishi
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - D Kawall
- Department of Physics, University of Massachusetts, Amherst, Massachusetts 01003-9337, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - M Kawashima
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Physics Department, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - A V Kazantsev
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
| | - S Kelly
- University of Colorado, Boulder, Colorado 80309, USA
| | - T Kempel
- Iowa State University, Ames, Iowa 50011, USA
| | - V Khachatryan
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - A Khanzadeev
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
| | - K M Kijima
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - J Kikuchi
- Waseda University, Advanced Research Institute for Science and Engineering, 17 Kikui-cho, Shinjuku-ku, Tokyo 162-0044, Japan
| | - A Kim
- Ewha Womans University, Seoul 120-750, Korea
| | - B I Kim
- Korea University, Seoul 02841, Korea
| | - C Kim
- Korea University, Seoul 02841, Korea
| | - D H Kim
- Myongji University, Yongin, Kyonggido 449-728, Korea
| | - D J Kim
- Helsinki Institute of Physics and University of Jyväskylä, P.O.Box 35, FI-40014 Jyväskylä, Finland
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - E Kim
- Department of Physics and Astronomy, Seoul National University, Seoul 151-742, Korea
| | - E-J Kim
- Chonbuk National University, Jeonju 561-756, Korea
| | - H J Kim
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - K-B Kim
- Chonbuk National University, Jeonju 561-756, Korea
| | - M Kim
- Department of Physics and Astronomy, Seoul National University, Seoul 151-742, Korea
| | - S H Kim
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - Y-J Kim
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - Y K Kim
- Hanyang University, Seoul 133-792, Korea
| | - Y-S Kim
- KAERI, Cyclotron Application Laboratory, Seoul 34057, Korea
| | - D Kincses
- ELTE, Eötvös Loránd University, H-1117 Budapest, Pázmány P. s. 1/A, Hungary
| | - E Kinney
- University of Colorado, Boulder, Colorado 80309, USA
| | - K Kiriluk
- University of Colorado, Boulder, Colorado 80309, USA
| | - Á Kiss
- ELTE, Eötvös Loránd University, H-1117 Budapest, Pázmány P. s. 1/A, Hungary
| | - E Kistenev
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - A Kiyomichi
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - J Klatsky
- Florida State University, Tallahassee, Florida 32306, USA
| | - J Klay
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - C Klein-Boesing
- Institut für Kernphysik, University of Münster, D-48149 Münster, Germany
| | - D Kleinjan
- University of California-Riverside, Riverside, California 92521, USA
| | - P Kline
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - L Kochenda
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
| | - V Kochetkov
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - Y Komatsu
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | - B Komkov
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
| | - M Konno
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - J Koster
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - D Kotchetkov
- University of California-Riverside, Riverside, California 92521, USA
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - D Kotov
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
- Saint Petersburg State Polytechnic University, St. Petersburg 195251, Russia
| | - A Kozlov
- Weizmann Institute, Rehovot 76100, Israel
| | - A Král
- Czech Technical University, Zikova 4, 166 36 Prague 6, Czech Republic
| | - A Kravitz
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - F Krizek
- Helsinki Institute of Physics and University of Jyväskylä, P.O.Box 35, FI-40014 Jyväskylä, Finland
| | - P J Kroon
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - J Kubart
- Charles University, Ovocný trh 5, Praha 1, 116 36 Prague, Czech Republic
- Institute of Physics, Academy of Sciences of the Czech Republic, Na Slovance 2, 182 21 Prague 8, Czech Republic
| | - G J Kunde
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - B Kurgyis
- ELTE, Eötvös Loránd University, H-1117 Budapest, Pázmány P. s. 1/A, Hungary
| | - N Kurihara
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - K Kurita
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Physics Department, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - M Kurosawa
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - M J Kweon
- Korea University, Seoul 02841, Korea
| | - Y Kwon
- University of Tennessee, Knoxville, Tennessee 37996, USA
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - G S Kyle
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - R Lacey
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - Y S Lai
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - J G Lajoie
- Iowa State University, Ames, Iowa 50011, USA
| | - D Layton
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - A Lebedev
- Iowa State University, Ames, Iowa 50011, USA
| | - Y Le Bornec
- IPN-Orsay, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, BP1, F-91406 Orsay, France
| | - S Leckey
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - B Lee
- Hanyang University, Seoul 133-792, Korea
| | - D M Lee
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J Lee
- Ewha Womans University, Seoul 120-750, Korea
- Sungkyunkwan University, Suwon 440-746, Korea
| | - K B Lee
- Korea University, Seoul 02841, Korea
| | - K S Lee
- Korea University, Seoul 02841, Korea
| | - M K Lee
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - S H Lee
- Iowa State University, Ames, Iowa 50011, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - S R Lee
- Chonbuk National University, Jeonju 561-756, Korea
| | - T Lee
- Department of Physics and Astronomy, Seoul National University, Seoul 151-742, Korea
| | - M J Leitch
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M A L Leite
- Universidade de São Paulo, Instituto de Física, Caixa Postal 66318, São Paulo CEP05315-970, Brazil
| | - M Leitgab
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - B Lenzi
- Universidade de São Paulo, Instituto de Física, Caixa Postal 66318, São Paulo CEP05315-970, Brazil
| | - Y H Leung
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - B Lewis
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - N A Lewis
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109-1040, USA
| | - X Li
- Science and Technology on Nuclear Data Laboratory, China Institute of Atomic Energy, Beijing 102413, People's Republic of China
| | - X Li
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - X H Li
- University of California-Riverside, Riverside, California 92521, USA
| | | | - P Liebing
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - H Lim
- Department of Physics and Astronomy, Seoul National University, Seoul 151-742, Korea
| | - S H Lim
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - L A Linden Levy
- University of Colorado, Boulder, Colorado 80309, USA
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - T Liška
- Czech Technical University, Zikova 4, 166 36 Prague 6, Czech Republic
| | - A Litvinenko
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - H Liu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - M X Liu
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S Lökös
- ELTE, Eötvös Loránd University, H-1117 Budapest, Pázmány P. s. 1/A, Hungary
- Eszterházy Károly University, Károly Róbert Campus, H-3200 Gyöngyös, Mátrai út 36, Hungary
| | - B Love
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - D Lynch
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - C F Maguire
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - T Majoros
- Debrecen University, H-4010 Debrecen, Egyetem tér 1, Hungary
| | - Y I Makdisi
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - M Makek
- Weizmann Institute, Rehovot 76100, Israel
- Department of Physics, Faculty of Science, University of Zagreb, Bijenička c. 32, HR-10002 Zagreb, Croatia
| | - A Malakhov
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - M D Malik
- University of New Mexico, Albuquerque, New Mexico 87131, USA
| | - A Manion
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - V I Manko
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
| | - E Mannel
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - Y Mao
- Peking University, Beijing 100871, People's Republic of China
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - L Mašek
- Charles University, Ovocný trh 5, Praha 1, 116 36 Prague, Czech Republic
- Institute of Physics, Academy of Sciences of the Czech Republic, Na Slovance 2, 182 21 Prague 8, Czech Republic
| | - H Masui
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Masumoto
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | - F Matathias
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M C McCain
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - M McCumber
- University of Colorado, Boulder, Colorado 80309, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - P L McGaughey
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - D McGlinchey
- University of Colorado, Boulder, Colorado 80309, USA
- Florida State University, Tallahassee, Florida 32306, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - C McKinney
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - N Means
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M Mendoza
- University of California-Riverside, Riverside, California 92521, USA
| | - B Meredith
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - Y Miake
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - T Mibe
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | - A C Mignerey
- University of Maryland, College Park, Maryland 20742, USA
| | - D E Mihalik
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - P Mikeš
- Charles University, Ovocný trh 5, Praha 1, 116 36 Prague, Czech Republic
- Institute of Physics, Academy of Sciences of the Czech Republic, Na Slovance 2, 182 21 Prague 8, Czech Republic
| | - K Miki
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - T E Miller
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - A Milov
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
- Weizmann Institute, Rehovot 76100, Israel
| | - S Mioduszewski
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - D K Mishra
- Bhabha Atomic Research Centre, Bombay 400 085, India
| | - G C Mishra
- Georgia State University, Atlanta, Georgia 30303, USA
| | - M Mishra
- Department of Physics, Banaras Hindu University, Varanasi 221005, India
| | - J T Mitchell
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - M Mitrovski
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - G Mitsuka
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - Y Miyachi
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - S Miyasaka
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - A K Mohanty
- Bhabha Atomic Research Centre, Bombay 400 085, India
| | - S Mohapatra
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - H J Moon
- Myongji University, Yongin, Kyonggido 449-728, Korea
| | - T Moon
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - Y Morino
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - A Morreale
- University of California-Riverside, Riverside, California 92521, USA
| | - D P Morrison
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S I Morrow
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - J M Moss
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S Motschwiller
- Muhlenberg College, Allentown, Pennsylvania 18104-5586, USA
| | - T V Moukhanova
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
| | | | - T Murakami
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - J Murata
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Physics Department, Rikkyo University, 3-34-1 Nishi-Ikebukuro, Toshima, Tokyo 171-8501, Japan
| | - A Mwai
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - T Nagae
- Kyoto University, Kyoto 606-8502, Japan
| | - S Nagamiya
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - K Nagashima
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - Y Nagata
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - J L Nagle
- University of Colorado, Boulder, Colorado 80309, USA
| | - M Naglis
- Weizmann Institute, Rehovot 76100, Israel
| | - M I Nagy
- ELTE, Eötvös Loránd University, H-1117 Budapest, Pázmány P. s. 1/A, Hungary
- Institute for Particle and Nuclear Physics, Wigner Research Centre for Physics, Hungarian Academy of Sciences (Wigner RCP, RMKI) H-1525 Budapest 114, POBox 49, Budapest, Hungary
| | - I Nakagawa
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - Y Nakamiya
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - K R Nakamura
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - T Nakamura
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - K Nakano
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - S Nam
- Ewha Womans University, Seoul 120-750, Korea
| | - C Nattrass
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - A Nederlof
- Muhlenberg College, Allentown, Pennsylvania 18104-5586, USA
| | - J Newby
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Nguyen
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M Nihashi
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - T Niida
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - B E Norman
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - R Nouicer
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - T Novák
- Eszterházy Károly University, Károly Róbert Campus, H-3200 Gyöngyös, Mátrai út 36, Hungary
| | - N Novitzky
- Helsinki Institute of Physics and University of Jyväskylä, P.O.Box 35, FI-40014 Jyväskylä, Finland
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - A S Nyanin
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
| | - J Nystrand
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - C Oakley
- Georgia State University, Atlanta, Georgia 30303, USA
| | - E O'Brien
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S X Oda
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - C A Ogilvie
- Iowa State University, Ames, Iowa 50011, USA
| | - H Ohnishi
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - I D Ojha
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - M Oka
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - K Okada
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - O O Omiwade
- Abilene Christian University, Abilene, Texas 79699, USA
| | - Y Onuki
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | | | - J D Osborn
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109-1040, USA
| | - A Oskarsson
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - I Otterlund
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - M Ouchida
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - K Ozawa
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - R Pak
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - D Pal
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - A P T Palounek
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - V Pantuev
- Institute for Nuclear Research of the Russian Academy of Sciences, prospekt 60-letiya Oktyabrya 7a, Moscow 117312, Russia
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - V Papavassiliou
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - B H Park
- Hanyang University, Seoul 133-792, Korea
| | - I H Park
- Ewha Womans University, Seoul 120-750, Korea
- Sungkyunkwan University, Suwon 440-746, Korea
| | - J Park
- Department of Physics and Astronomy, Seoul National University, Seoul 151-742, Korea
| | - S Park
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Department of Physics and Astronomy, Seoul National University, Seoul 151-742, Korea
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - S K Park
- Korea University, Seoul 02841, Korea
| | - W J Park
- Korea University, Seoul 02841, Korea
| | - S F Pate
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - L Patel
- Georgia State University, Atlanta, Georgia 30303, USA
| | - M Patel
- Iowa State University, Ames, Iowa 50011, USA
| | - H Pei
- Iowa State University, Ames, Iowa 50011, USA
| | - J-C Peng
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - W Peng
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - H Pereira
- Dapnia, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - D V Perepelitsa
- University of Colorado, Boulder, Colorado 80309, USA
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - V Peresedov
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - D Yu Peressounko
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
| | - C E PerezLara
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - R Petti
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - C Pinkenburg
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - R P Pisani
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - M Proissl
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - M L Purschke
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - A K Purwar
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - H Qu
- Abilene Christian University, Abilene, Texas 79699, USA
- Georgia State University, Atlanta, Georgia 30303, USA
| | - P V Radzevich
- Saint Petersburg State Polytechnic University, St. Petersburg 195251, Russia
| | - J Rak
- Iowa State University, Ames, Iowa 50011, USA
- Helsinki Institute of Physics and University of Jyväskylä, P.O.Box 35, FI-40014 Jyväskylä, Finland
- University of New Mexico, Albuquerque, New Mexico 87131, USA
| | - A Rakotozafindrabe
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | | | - K F Read
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - S Rembeczki
- Florida Institute of Technology, Melbourne, Florida 32901, USA
| | - M Reuter
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - K Reygers
- Institut für Kernphysik, University of Münster, D-48149 Münster, Germany
| | - D Reynolds
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - V Riabov
- National Research Nuclear University, MEPhI, Moscow Engineering Physics Institute, Moscow 115409, Russia
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
| | - Y Riabov
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
- Saint Petersburg State Polytechnic University, St. Petersburg 195251, Russia
| | - E Richardson
- University of Maryland, College Park, Maryland 20742, USA
| | - D Richford
- Baruch College, City University of New York, New York, New York 10010, USA
| | - T Rinn
- Iowa State University, Ames, Iowa 50011, USA
| | - D Roach
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - G Roche
- LPC, Université Blaise Pascal, CNRS-IN2P3, Clermont-Fd, 63177 Aubiere Cedex, France
| | - S D Rolnick
- University of California-Riverside, Riverside, California 92521, USA
| | - A Romana
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | - M Rosati
- Iowa State University, Ames, Iowa 50011, USA
| | - C A Rosen
- University of Colorado, Boulder, Colorado 80309, USA
| | - S S E Rosendahl
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - P Rosnet
- LPC, Université Blaise Pascal, CNRS-IN2P3, Clermont-Fd, 63177 Aubiere Cedex, France
| | - Z Rowan
- Baruch College, City University of New York, New York, New York 10010, USA
| | - P Rukoyatkin
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - J Runchey
- Iowa State University, Ames, Iowa 50011, USA
| | - P Ružička
- Institute of Physics, Academy of Sciences of the Czech Republic, Na Slovance 2, 182 21 Prague 8, Czech Republic
| | - V L Rykov
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - S S Ryu
- Yonsei University, IPAP, Seoul 120-749, Korea
| | - B Sahlmueller
- Institut für Kernphysik, University of Münster, D-48149 Münster, Germany
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - N Saito
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - T Sakaguchi
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- Waseda University, Advanced Research Institute for Science and Engineering, 17 Kikui-cho, Shinjuku-ku, Tokyo 162-0044, Japan
| | - S Sakai
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - K Sakashita
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - H Sakata
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - H Sako
- Advanced Science Research Center, Japan Atomic Energy Agency, 2-4 Shirakata Shirane, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
| | - V Samsonov
- National Research Nuclear University, MEPhI, Moscow Engineering Physics Institute, Moscow 115409, Russia
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
| | - M Sano
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Sano
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- Waseda University, Advanced Research Institute for Science and Engineering, 17 Kikui-cho, Shinjuku-ku, Tokyo 162-0044, Japan
| | - M Sarsour
- Georgia State University, Atlanta, Georgia 30303, USA
| | - H D Sato
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - S Sato
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Advanced Science Research Center, Japan Atomic Energy Agency, 2-4 Shirakata Shirane, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - T Sato
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Sawada
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | - B K Schmoll
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - K Sedgwick
- University of California-Riverside, Riverside, California 92521, USA
| | - J Seele
- University of Colorado, Boulder, Colorado 80309, USA
| | - R Seidl
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | | | - V Semenov
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
- Institute for Nuclear Research of the Russian Academy of Sciences, prospekt 60-letiya Oktyabrya 7a, Moscow 117312, Russia
| | - A Sen
- Georgia State University, Atlanta, Georgia 30303, USA
- Iowa State University, Ames, Iowa 50011, USA
| | - R Seto
- University of California-Riverside, Riverside, California 92521, USA
| | - D Sharma
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
- Weizmann Institute, Rehovot 76100, Israel
| | - T K Shea
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - I Shein
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - A Shevel
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - T-A Shibata
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- Department of Physics, Tokyo Institute of Technology, Oh-okayama, Meguro, Tokyo 152-8551, Japan
| | - K Shigaki
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - M Shimomura
- Iowa State University, Ames, Iowa 50011, USA
- Nara Women's University, Kita-uoya Nishi-machi, Nara 630-8506, Japan
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - T Shohjoh
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - K Shoji
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - P Shukla
- Bhabha Atomic Research Centre, Bombay 400 085, India
| | - A Sickles
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - C L Silva
- Iowa State University, Ames, Iowa 50011, USA
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Universidade de São Paulo, Instituto de Física, Caixa Postal 66318, São Paulo CEP05315-970, Brazil
| | - D Silvermyr
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - C Silvestre
- Dapnia, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - K S Sim
- Korea University, Seoul 02841, Korea
| | - B K Singh
- Department of Physics, Banaras Hindu University, Varanasi 221005, India
| | - C P Singh
- Department of Physics, Banaras Hindu University, Varanasi 221005, India
| | - V Singh
- Department of Physics, Banaras Hindu University, Varanasi 221005, India
| | - M J Skoby
- Department of Physics, University of Michigan, Ann Arbor, Michigan 48109-1040, USA
| | - S Skutnik
- Iowa State University, Ames, Iowa 50011, USA
| | - M Slunečka
- Charles University, Ovocný trh 5, Praha 1, 116 36 Prague, Czech Republic
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - W C Smith
- Abilene Christian University, Abilene, Texas 79699, USA
| | - A Soldatov
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - R A Soltz
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - W E Sondheim
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - S P Sorensen
- University of Tennessee, Knoxville, Tennessee 37996, USA
| | - I V Sourikova
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - F Staley
- Dapnia, CEA Saclay, F-91191 Gif-sur-Yvette, France
| | - P W Stankus
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - E Stenlund
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - M Stepanov
- Department of Physics, University of Massachusetts, Amherst, Massachusetts 01003-9337, USA
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - A Ster
- Institute for Particle and Nuclear Physics, Wigner Research Centre for Physics, Hungarian Academy of Sciences (Wigner RCP, RMKI) H-1525 Budapest 114, POBox 49, Budapest, Hungary
| | - S P Stoll
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - T Sugitate
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - C Suire
- IPN-Orsay, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, BP1, F-91406 Orsay, France
| | - A Sukhanov
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - J P Sullivan
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - J Sun
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - Z Sun
- Debrecen University, H-4010 Debrecen, Egyetem tér 1, Hungary
| | - J Sziklai
- Institute for Particle and Nuclear Physics, Wigner Research Centre for Physics, Hungarian Academy of Sciences (Wigner RCP, RMKI) H-1525 Budapest 114, POBox 49, Budapest, Hungary
| | - T Tabaru
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S Takagi
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - E M Takagui
- Universidade de São Paulo, Instituto de Física, Caixa Postal 66318, São Paulo CEP05315-970, Brazil
| | - A Takahara
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - A Taketani
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - R Tanabe
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - K H Tanaka
- KEK, High Energy Accelerator Research Organization, Tsukuba, Ibaraki 305-0801, Japan
| | - Y Tanaka
- Nagasaki Institute of Applied Science, Nagasaki-shi, Nagasaki 851-0193, Japan
| | - S Taneja
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - K Tanida
- Advanced Science Research Center, Japan Atomic Energy Agency, 2-4 Shirakata Shirane, Tokai-mura, Naka-gun, Ibaraki-ken 319-1195, Japan
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Seoul National University, Seoul 151-742, Korea
| | - M J Tannenbaum
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - S Tarafdar
- Department of Physics, Banaras Hindu University, Varanasi 221005, India
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - A Taranenko
- National Research Nuclear University, MEPhI, Moscow Engineering Physics Institute, Moscow 115409, Russia
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - P Tarján
- Debrecen University, H-4010 Debrecen, Egyetem tér 1, Hungary
| | - E Tennant
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - H Themann
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - D Thomas
- Abilene Christian University, Abilene, Texas 79699, USA
| | - T L Thomas
- University of New Mexico, Albuquerque, New Mexico 87131, USA
| | - R Tieulent
- IPNL, CNRS/IN2P3, Univ Lyon, Universit Lyon 1, F-69622 Villeurbanne, France
| | - T Todoroki
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Togawa
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - A Toia
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - J Tojo
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - L Tomášek
- Institute of Physics, Academy of Sciences of the Czech Republic, Na Slovance 2, 182 21 Prague 8, Czech Republic
| | - M Tomášek
- Czech Technical University, Zikova 4, 166 36 Prague 6, Czech Republic
- Institute of Physics, Academy of Sciences of the Czech Republic, Na Slovance 2, 182 21 Prague 8, Czech Republic
| | - Y Tomita
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - H Torii
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - R S Towell
- Abilene Christian University, Abilene, Texas 79699, USA
| | - V-N Tram
- Laboratoire Leprince-Ringuet, Ecole Polytechnique, CNRS-IN2P3, Route de Saclay, F-91128 Palaiseau, France
| | - I Tserruya
- Weizmann Institute, Rehovot 76100, Israel
| | - Y Tsuchimoto
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - T Tsuji
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - S K Tuli
- Department of Physics, Banaras Hindu University, Varanasi 221005, India
| | - H Tydesjö
- Department of Physics, Lund University, Box 118, SE-221 00 Lund, Sweden
| | - N Tyurin
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - Y Ueda
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - B Ujvari
- Debrecen University, H-4010 Debrecen, Egyetem tér 1, Hungary
| | - C Vale
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Iowa State University, Ames, Iowa 50011, USA
| | - H Valle
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - H W van Hecke
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
| | - M Vargyas
- ELTE, Eötvös Loránd University, H-1117 Budapest, Pázmány P. s. 1/A, Hungary
- Institute for Particle and Nuclear Physics, Wigner Research Centre for Physics, Hungarian Academy of Sciences (Wigner RCP, RMKI) H-1525 Budapest 114, POBox 49, Budapest, Hungary
| | - E Vazquez-Zambrano
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - A Veicht
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - J Velkovska
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - R Vértesi
- Debrecen University, H-4010 Debrecen, Egyetem tér 1, Hungary
- Institute for Particle and Nuclear Physics, Wigner Research Centre for Physics, Hungarian Academy of Sciences (Wigner RCP, RMKI) H-1525 Budapest 114, POBox 49, Budapest, Hungary
| | - A A Vinogradov
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
| | - M Virius
- Czech Technical University, Zikova 4, 166 36 Prague 6, Czech Republic
| | - A Vossen
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - V Vrba
- Czech Technical University, Zikova 4, 166 36 Prague 6, Czech Republic
- Institute of Physics, Academy of Sciences of the Czech Republic, Na Slovance 2, 182 21 Prague 8, Czech Republic
| | - E Vznuzdaev
- PNPI, Petersburg Nuclear Physics Institute, Gatchina 188300, Leningrad region, Russia
| | - M Wagner
- Kyoto University, Kyoto 606-8502, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
| | - D Walker
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
| | - X R Wang
- New Mexico State University, Las Cruces, New Mexico 88003, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - D Watanabe
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - K Watanabe
- Tomonaga Center for the History of the Universe, University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - Y Watanabe
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - Y S Watanabe
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
| | - F Wei
- Iowa State University, Ames, Iowa 50011, USA
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - R Wei
- Chemistry Department, Stony Brook University, SUNY, Stony Brook, New York 11794-3400, USA
| | - J Wessels
- Institut für Kernphysik, University of Münster, D-48149 Münster, Germany
| | - S N White
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - N Willis
- IPN-Orsay, Université Paris-Sud, CNRS/IN2P3, Université Paris-Saclay, BP1, F-91406 Orsay, France
| | - D Winter
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - S Wolin
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - C P Wong
- Georgia State University, Atlanta, Georgia 30303, USA
| | - C L Woody
- Physics Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - R M Wright
- Abilene Christian University, Abilene, Texas 79699, USA
| | - M Wysocki
- University of Colorado, Boulder, Colorado 80309, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - B Xia
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - W Xie
- University of California-Riverside, Riverside, California 92521, USA
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - C Xu
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - Q Xu
- Vanderbilt University, Nashville, Tennessee 37235, USA
| | - Y L Yamaguchi
- Center for Nuclear Study, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo 113-0033, Japan
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
- Department of Physics and Astronomy, Stony Brook University, SUNY, Stony Brook, New York 11794-3800, USA
- Waseda University, Advanced Research Institute for Science and Engineering, 17 Kikui-cho, Shinjuku-ku, Tokyo 162-0044, Japan
| | - K Yamaura
- Hiroshima University, Kagamiyama, Higashi-Hiroshima 739-8526, Japan
| | - R Yang
- University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, USA
| | - A Yanovich
- IHEP Protvino, State Research Center of Russian Federation, Institute for High Energy Physics, Protvino 142281, Russia
| | - Z Yasin
- University of California-Riverside, Riverside, California 92521, USA
| | - J Ying
- Georgia State University, Atlanta, Georgia 30303, USA
| | - S Yokkaichi
- RIKEN Nishina Center for Accelerator-Based Science, Wako, Saitama 351-0198, Japan
- RIKEN BNL Research Center, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - J H Yoo
- Korea University, Seoul 02841, Korea
| | - Z You
- Los Alamos National Laboratory, Los Alamos, New Mexico 87545, USA
- Peking University, Beijing 100871, People's Republic of China
| | - G R Young
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - I Younus
- Physics Department, Lahore University of Management Sciences, Lahore 54792, Pakistan
- University of New Mexico, Albuquerque, New Mexico 87131, USA
| | - H Yu
- New Mexico State University, Las Cruces, New Mexico 88003, USA
| | - I E Yushmanov
- National Research Center "Kurchatov Institute", Moscow 123098, Russia
| | - W A Zajc
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
| | - O Zaudtke
- Institut für Kernphysik, University of Münster, D-48149 Münster, Germany
| | - A Zelenski
- Collider-Accelerator Department, Brookhaven National Laboratory, Upton, New York 11973-5000, USA
| | - C Zhang
- Columbia University, New York, New York 10027, USA and Nevis Laboratories, Irvington, New York 10533, USA
- Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, USA
| | - S Zharko
- Saint Petersburg State Polytechnic University, St. Petersburg 195251, Russia
| | - S Zhou
- Science and Technology on Nuclear Data Laboratory, China Institute of Atomic Energy, Beijing 102413, People's Republic of China
| | - J Zimamyi
- Institute for Particle and Nuclear Physics, Wigner Research Centre for Physics, Hungarian Academy of Sciences (Wigner RCP, RMKI) H-1525 Budapest 114, POBox 49, Budapest, Hungary
| | - L Zolin
- Joint Institute for Nuclear Research, Dubna 141980, Moscow Region, Russia
| | - L Zou
- University of California-Riverside, Riverside, California 92521, USA
| |
Collapse
|
40
|
Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell 2019; 71:606-620.e7. [PMID: 30118680 DOI: 10.1016/j.molcel.2018.07.030] [Citation(s) in RCA: 448] [Impact Index Per Article: 89.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2018] [Revised: 06/26/2018] [Accepted: 07/23/2018] [Indexed: 11/17/2022]
Abstract
Metformin has been reported to possess antitumor activity and maintain high cytotoxic T lymphocyte (CTL) immune surveillance. However, the functions and detailed mechanisms of metformin's role in cancer immunity are not fully understood. Here, we show that metformin increases CTL activity by reducing the stability and membrane localization of programmed death ligand-1 (PD-L1). Furthermore, we discover that AMP-activated protein kinase (AMPK) activated by metformin directly phosphorylates S195 of PD-L1. S195 phosphorylation induces abnormal PD-L1 glycosylation, resulting in its ER accumulation and ER-associated protein degradation (ERAD). Consistently, tumor tissues from metformin-treated breast cancer patients exhibit reduced PD-L1 levels with AMPK activation. Blocking the inhibitory signal of PD-L1 by metformin enhances CTL activity against cancer cells. Our findings identify a new regulatory mechanism of PD-L1 expression through the ERAD pathway and suggest that the metformin-CTLA4 blockade combination has the potential to increase the efficacy of immunotherapy.
Collapse
Affiliation(s)
- Jong-Ho Cha
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Tumor Microenvironment Global Core Research Center, College of Pharmacy, Seoul National University, Seoul 151-742, Korea
| | - Wen-Hao Yang
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Weiya Xia
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Yongkun Wei
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Li-Chuan Chan
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX 77030, USA
| | - Seung-Oe Lim
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Chia-Wei Li
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Taewan Kim
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Shih-Shin Chang
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Heng-Huan Lee
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Jennifer L Hsu
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan
| | - Hung-Ling Wang
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan
| | - Chu-Wei Kuo
- Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan
| | - Wei-Chao Chang
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan
| | - Sirwan Hadad
- Department of Surgery, University of Sheffield, Western Bank, Sheffield S10 2TN, UK
| | - Colin A Purdie
- Department of Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
| | - Aaron M McCoy
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Shirong Cai
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Yizheng Tu
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Jennifer K Litton
- Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Elizabeth A Mittendorf
- Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Stacy L Moulder
- Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - William F Symmans
- Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Alastair M Thompson
- Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Helen Piwnica-Worms
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX 77030, USA
| | - Chung-Hsuan Chen
- Genomics Research Center, Academia Sinica, Nankang, Taipei 115, Taiwan
| | - Kay-Hooi Khoo
- Institute of Biological Chemistry, Academia Sinica, Nankang, Taipei 115, Taiwan
| | - Mien-Chie Hung
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan; Department of Biotechnology, Asia University, Taichung 413, Taiwan.
| |
Collapse
|
41
|
Chang WC, Chan SKW, Lee EHM, Hui CLM, Chen EYH. Extended early intervention versus standard psychiatric care for adults with first-episode psychosis. Hong Kong Med J 2019; 25 Suppl 3:4-8. [PMID: 30792363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Open
Affiliation(s)
- W C Chang
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong
| | - S K W Chan
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong
| | - E H M Lee
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
| | - C L M Hui
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
| | - E Y H Chen
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong
| |
Collapse
|
42
|
Chen EYH, Chang WC, Hui CLM, Chan SKW, Lee EHM, Wong GHY. Duration of early intervention for psychosis: 2 years versus 3 years. Hong Kong Med J 2019; 25 Suppl 2:10-14. [PMID: 30674701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023] Open
Affiliation(s)
- E Y H Chen
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong
| | - W C Chang
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong
| | - C L M Hui
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
| | - S K W Chan
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
- State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong
| | - E H M Lee
- Department of Psychiatry, LKS Faculty of Medicine, The University of Hong Kong
| | - G H Y Wong
- Department of Social Work and Social Administration, The University of Hong Kong
| |
Collapse
|
43
|
Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, Zhang Z, Wang YV, Huang L, Yuan M, Xia W, Chang WC, Huang WC, Liu CL, Chang YC, Liu J, Wu Y, Jin VX, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Mol Cell 2019; 69:279-291.e5. [PMID: 29351847 DOI: 10.1016/j.molcel.2017.12.024] [Citation(s) in RCA: 125] [Impact Index Per Article: 25.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Revised: 11/11/2017] [Accepted: 12/22/2017] [Indexed: 12/12/2022]
Abstract
Sustained energy starvation leads to activation of AMP-activated protein kinase (AMPK), which coordinates energy status with numerous cellular processes including metabolism, protein synthesis, and autophagy. Here, we report that AMPK phosphorylates the histone methyltransferase EZH2 at T311 to disrupt the interaction between EZH2 and SUZ12, another core component of the polycomb repressive complex 2 (PRC2), leading to attenuated PRC2-dependent methylation of histone H3 at Lys27. As such, PRC2 target genes, many of which are known tumor suppressors, were upregulated upon T311-EZH2 phosphorylation, which suppressed tumor cell growth both in cell culture and mouse xenografts. Pathologically, immunohistochemical analyses uncovered a positive correlation between AMPK activity and pT311-EZH2, and higher pT311-EZH2 correlates with better survival in both ovarian and breast cancer patients. Our finding suggests that AMPK agonists might be promising sensitizers for EZH2-targeting cancer therapies.
Collapse
Affiliation(s)
- Lixin Wan
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
| | - Kexin Xu
- Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA; Department of Medical Oncology and Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA
| | - Yongkun Wei
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Jinfang Zhang
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Tao Han
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
| | | | - Zhao Zhang
- Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
| | - Yao Vickie Wang
- Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
| | - Liyu Huang
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Chinese National Human Genome Center at Shanghai, Shanghai 201203, PRC
| | - Min Yuan
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Weiya Xia
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Wei-Chao Chang
- Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan
| | - Wen-Chien Huang
- Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan
| | - Chien-Liang Liu
- Department of Surgery, Mackay Memorial Hospital, Taipei, Taiwan
| | | | - Jinsong Liu
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Yun Wu
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Victor X Jin
- Department of Molecular Medicine, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
| | - Xiangpeng Dai
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Jianfeng Guo
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PRC
| | - Jia Liu
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Cardiovascular Research Center, Xi'an Jiaotong University School of Medicine, Xi'an 710061, PRC
| | - Shulong Jiang
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Department of Oncology, Jining First People's Hospital, Jining, Shandong 272111, PRC; Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, PRC
| | - Jin Li
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Department of Urology, 254th Hospital of PLA, Tianjin 300142, PRC
| | - John M Asara
- Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Myles Brown
- Department of Medical Oncology and Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
| | - Mien-Chie Hung
- Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung 404, Taiwan.
| | - Wenyi Wei
- Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
| |
Collapse
|
44
|
Li AWY, Hui CLM, Lee EHM, Chang WC, Chan SKW, Chen EYH. Gender differences in correlates of cognition in first-episode psychosis. Psychiatry Res 2019; 271:412-420. [PMID: 30537663 DOI: 10.1016/j.psychres.2018.12.011] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 11/19/2018] [Accepted: 12/02/2018] [Indexed: 01/01/2023]
Abstract
Studies of gender cognitive differences in schizophrenia have reported mixed results. This study examined cognitive correlates including demographics, symptoms and functioning in men and women in a large sample of first-episode adult-onset psychosis patients. Detailed demographic, clinical and functioning data were collected from 360 first-episode patients upon admission into an early intervention service for psychotic disorders. They were also administered a comprehensive neurocognitive battery. Correlation analyses showed that memory and working memory were more significantly associated with onset age, negative symptoms and side effects in women. Processing speed correlated with antipsychotic dosage in men and side effects in women. Selective attention correlated with reality distortion and negative symptoms in women, and onset age and education in men. Executive function correlated with onset age and reality distortion in women. All cognitive domains significantly correlated with educational level and functioning in both genders. Negative symptoms explained significant variability in cognition in both genders, while reality distortion, side effects and affective symptoms were significant factors that differentiated between genders. Although there are similarities in cognitive deficits, considerable heterogeneity exists in associations of symptoms and cognition in men and women. Results facilitate individualised tailoring of interventions, including cognitive remediation therapy.
Collapse
Affiliation(s)
- Adrienne W Y Li
- Department of Psychiatry, University of Hong Kong, Hong Kong, China; Department of Clinical, Educational and Health Psychology, University College London, United Kingdom
| | - Christy L M Hui
- Department of Psychiatry, University of Hong Kong, Hong Kong, China.
| | - Edwin H M Lee
- Department of Psychiatry, University of Hong Kong, Hong Kong, China
| | - W C Chang
- Department of Psychiatry, University of Hong Kong, Hong Kong, China; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong, China
| | - Sherry K W Chan
- Department of Psychiatry, University of Hong Kong, Hong Kong, China; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong, China
| | - Eric Y H Chen
- Department of Psychiatry, University of Hong Kong, Hong Kong, China; State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Hong Kong, China
| |
Collapse
|
45
|
Chang WC, Lee HC, Chan SI, Chiu SY, Lee HM, Chan KW, Wong MC, Chan KL, Yeung WS, Choy LW, Chong SY, Siu MW, Lo TL, Yan WC, Ng MK, Poon LT, Pang PF, Lam WC, Wong YC, Chung WS, Mo YM, Lui SY, Hui LM, Chen EYH. Negative symptom dimensions differentially impact on functioning in individuals at-risk for psychosis. Schizophr Res 2018; 202:310-315. [PMID: 29935882 DOI: 10.1016/j.schres.2018.06.041] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/01/2017] [Revised: 04/20/2018] [Accepted: 06/14/2018] [Indexed: 12/24/2022]
Affiliation(s)
- W C Chang
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong; State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong.
| | - H C Lee
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong
| | - S I Chan
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong
| | - S Y Chiu
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong
| | - H M Lee
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong
| | - K W Chan
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong; State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong
| | - M C Wong
- Department of Psychiatry, Queen Mary Hospital, Hong Kong
| | - K L Chan
- Department of Psychiatry, Queen Mary Hospital, Hong Kong
| | - W S Yeung
- Department of Psychiatry, Pamela Youde Nethersole Eastern Hospital, Hong Kong
| | - L W Choy
- Department of Psychiatry, Pamela Youde Nethersole Eastern Hospital, Hong Kong
| | - S Y Chong
- Department of Psychiatry, Kwai Chung Hospital, Hong Kong
| | - M W Siu
- Department of Psychiatry, Kwai Chung Hospital, Hong Kong
| | - T L Lo
- Department of Psychiatry, Kwai Chung Hospital, Hong Kong
| | - W C Yan
- Department of Psychiatry, Kowloon Hospital, Hong Kong
| | - M K Ng
- Department of Psychiatry, Kowloon Hospital, Hong Kong
| | - L T Poon
- Department of Psychiatry, United Christian Hospital, Hong Kong
| | - P F Pang
- Department of Psychiatry, United Christian Hospital, Hong Kong
| | - W C Lam
- Department of Psychiatry, United Christian Hospital, Hong Kong
| | - Y C Wong
- Department of Psychiatry, Tai Po Hospital, Hong Kong
| | - W S Chung
- Department of Psychiatry, Tai Po Hospital, Hong Kong
| | - Y M Mo
- Department of Psychiatry, Alice Ho Miu Ling Nethersole Hospital, Hong Kong
| | - S Y Lui
- Department of Psychiatry, Castle Peak Hospital, Hong Kong
| | - L M Hui
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong
| | - E Y H Chen
- Department of Psychiatry, The University of Hong Kong, Queen Mary Hospital, Hong Kong; State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong
| |
Collapse
|
46
|
Tu CY, Wang BW, Cheng FJ, Chen CH, Hsia TC, Wei YL, Chen CY, Hsieh IS, Yeh YL, Wang LY, Chen CM, Chang WC, Huang WC. Incense burning smoke sensitizes lung cancer cells to EGFR TKI by inducing AREG expression. Am J Cancer Res 2018; 8:2575-2589. [PMID: 30662813 PMCID: PMC6325473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2018] [Accepted: 11/13/2018] [Indexed: 06/09/2023] Open
Abstract
Incense burning is common in Asian countries due to the religious beliefs. Environmental exposure to incense burning smoke is a potential risk factor for tumor development and progression of non-small cell lung cancer (NSCLC). Eastern Asia ethnic origin is strongly associated the clinical benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC patients. However, the impact of the oriental custom of incense burning on the cancer progression and the EGFR TKI-sensitivity of NSCLC remains unclear. Our results showed that long-term exposure to incense burning extract (IBE) increases the cellular proliferation with S phase accumulation and the motility activity of NSCLCs. Interestingly, IBE enhances EGFR signaling activity without affecting its genetic status, and increases the cellular sensitivity of NSCLC cell lines to EGFR TKIs. Auramine, a yellow dye for making incense sticks, was identified as a residual composition in the burning incense smoke, and showed similar EGFR TKI-sensitizing effects. Furthermore, IBE or auramine transcriptionally induce EGFR ligand amphiregulin (AREG) expression for the enhancement of EGFR activity. Neutralization of AREG reduced the viability of IBE-treated cells. These results indicated that exposure to incent smoke may enhance NSCLC progression and their sensitivity to EGFR TKIs through increasing their oncogenic addiction to AREG-induced EGFR signaling.
Collapse
Affiliation(s)
- Chih-Yen Tu
- Department of Life Science, National Chung Hsing UniversityTaichung 402, Taiwan
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University HospitalTaichung 404, Taiwan
- School of Medicine, China Medical UniversityTaichung 404, Taiwan
| | - Bo-Wei Wang
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
| | - Fang-Ju Cheng
- Graduate Institute of Basic Medical Science, China Medical UniversityTaichung 404, Taiwan
| | - Chia-Hung Chen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University HospitalTaichung 404, Taiwan
- School of Medicine, China Medical UniversityTaichung 404, Taiwan
- Department of Respiratory Therapy, China Medical UniversityTaichung 404, Taiwan
- Graduate Institute of Clinical Medical Science, China Medical UniversityTaichung 404, Taiwan
| | - Te-Chun Hsia
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University HospitalTaichung 404, Taiwan
- Department of Respiratory Therapy, China Medical UniversityTaichung 404, Taiwan
- Hyperbaric Oxygen Therapy Center, Department of Internal Medicine, China Medical University HospitalTaichung 404, Taiwan
| | - Ya-Ling Wei
- Center for Molecular Medicine, China Medical University and HospitalTaichung 404, Taiwan
| | - Chih-Yi Chen
- Department of Surgery, Chang Shan Medical UniversityTaichung, Taiwan
| | - I-Shan Hsieh
- School of Medicine, China Medical UniversityTaichung 404, Taiwan
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
| | - Yi-Lun Yeh
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
| | - Li-Yun Wang
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
| | - Chuan-Mu Chen
- The iEGG and Animal Biotechnology Center, Ph.D. Program in Translational Medicine, National Chung Hsing UniversityTaichung 402, Taiwan
| | - Wei-Chao Chang
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
- Center for Molecular Medicine, China Medical University and HospitalTaichung 404, Taiwan
- The Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia SinicaTaichung 404, Taiwan
| | - Wei-Chien Huang
- Graduate Institute of Biomedical Sciences, China Medical UniversityTaichung 404, Taiwan
- Center for Molecular Medicine, China Medical University and HospitalTaichung 404, Taiwan
- The Ph.D. Program for Cancer Biology and Drug Discovery, China Medical University and Academia SinicaTaichung 404, Taiwan
- Department of Biotechnology, College of Health Science, Asia UniversityTaichung 413, Taiwan
- Drug Development Center, China Medical UniversityTaichung, Taiwan
| |
Collapse
|
47
|
Kohri H, Shiu SH, Chang WC, Yanai Y, Ahn DS, Ahn JK, Chen JY, Daté S, Ejiri H, Fujimura H, Fujiwara M, Fukui S, Gohn W, Hicks K, Hosaka A, Hotta T, Hwang SH, Imai K, Ishikawa T, Joo K, Kato Y, Kon Y, Lee HS, Maeda Y, Mibe T, Miyabe M, Morino Y, Muramatsu N, Nakano T, Nakatsugawa Y, Nam SI, Niiyama M, Noumi H, Ohashi Y, Ohta T, Oka M, Parker JD, Rangacharyulu C, Ryu SY, Sawada T, Shimizu H, Strokovsky EA, Sugaya Y, Sumihama M, Tsunemi T, Uchida M, Ungaro M, Wang SY, Yosoi M. Differential Cross Section and Photon-Beam Asymmetry for the γ[over →]p → π^{-}Δ^{++}(1232) Reaction at Forward π^{-} Angles for E_{γ}=1.5-2.95 GeV. Phys Rev Lett 2018; 120:202004. [PMID: 29864366 DOI: 10.1103/physrevlett.120.202004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 03/11/2018] [Indexed: 06/08/2023]
Abstract
Differential cross sections and photon-beam asymmetries for the γ[over →]p→π^{-}Δ^{++}(1232) reaction have been measured for 0.7<cosθ_{π}^{c.m.}<1 and E_{γ}=1.5-2.95 GeV at SPring-8/LEPS. The first-ever high statistics cross-section data are obtained in this kinematical region, and the asymmetry data for 1.5<E_{γ}(GeV)<2.8 are obtained for the first time. This reaction has a unique feature for studying the production mechanisms of a pure uu[over ¯] quark pair in the final state from the proton. Although there is no distinct peak structure in the cross sections, a non-negligible excess over the theoretical predictions is observed at E_{γ}=1.5-1.8 GeV. The asymmetries are found to be negative in most of the present kinematical regions, suggesting the dominance of π exchange in the t channel. The negative asymmetries at forward meson production angles are different from the asymmetries previously measured for the photoproduction reactions producing a dd[over ¯] or an ss[over ¯] quark pair in the final state. Advanced theoretical models introducing nucleon resonances and additional unnatural-parity exchanges are needed to reproduce the present data.
Collapse
Affiliation(s)
- H Kohri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - S H Shiu
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
- Department of Physics, National Central University, Taoyuan City 32001, Taiwan
| | - W C Chang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - Y Yanai
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - D S Ahn
- RIKEN Nishina Center, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
| | - J K Ahn
- Department of Physics, Korea University, Seoul 02841, Republic of Korea
| | - J Y Chen
- Light Source Division, National Synchrotron Radiation Research Center, Hsinchu 30076, Taiwan
| | - S Daté
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - H Ejiri
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H Fujimura
- Wakayama Medical College, Wakayama 641-8509, Japan
| | - M Fujiwara
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- National Institutes for Quantum and Radiological Science and Technology, Tokai, Ibaraki 319-1195, Japan
| | - S Fukui
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - W Gohn
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - K Hicks
- Department of Physics and Astronomy, Ohio University, Athens, Ohio 45701, USA
| | - A Hosaka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Hotta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S H Hwang
- Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
| | - K Imai
- Advanced Science Research Center, Japan Atomic Energy Agency, Tokai, Ibaraki 319-1195, Japan
| | - T Ishikawa
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - K Joo
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - Y Kato
- Kobayashi-Maskawa Institute, Nagoya University, Nagoya, Aichi 464-8602, Japan
| | - Y Kon
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - H S Lee
- Rare Isotope Science Project, Institute for Basic Science, Daejeon 34047, Korea
| | - Y Maeda
- Proton Therapy Center, Fukui Prefectural Hospital, Fukui 910-8526, Japan
| | - T Mibe
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - M Miyabe
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - Y Morino
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - N Muramatsu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - T Nakano
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Nakatsugawa
- High Energy Accelerator Organization (KEK), Tsukuba, Ibaraki 305-0801, Japan
| | - S I Nam
- Department of Physics, Pukyong National University (PKNU), Busan 608-737, Republic of Korea
| | - M Niiyama
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - H Noumi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - Y Ohashi
- Japan Synchrotron Radiation Research Institute, Sayo, Hyogo 679-5143, Japan
| | - T Ohta
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Oka
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - J D Parker
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - C Rangacharyulu
- Department of Physics and Engineering Physics, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E2, Canada
| | - S Y Ryu
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - T Sawada
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
- Physics Department, University of Michigan, Michigan 48109-1040, USA
| | - H Shimizu
- Research Center for Electron Photon Science, Tohoku University, Sendai, Miyagi 982-0826, Japan
| | - E A Strokovsky
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
- Joint Institute for Nuclear Research, Dubna, Moscow Region 142281, Russia
| | - Y Sugaya
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - M Sumihama
- Department of Education, Gifu University, Gifu 501-1193, Japan
| | - T Tsunemi
- Department of Physics, Kyoto University, Kyoto 606-8502, Japan
| | - M Uchida
- Department of Physics, Tokyo Institute of Technology, Tokyo 152-8551, Japan
| | - M Ungaro
- Department of Physics, University of Connecticut, Storrs, Connecticut 06269-3046, USA
| | - S Y Wang
- Institute of Physics, Academia Sinica, Taipei 11529, Taiwan
| | - M Yosoi
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| |
Collapse
|
48
|
Chien Y, Chou SJ, Chang YL, Leu HB, Yang YP, Tsai PH, Lai YH, Chen KH, Chang WC, Sung SH, Yu WC. Inhibition of Arachidonate 12/15-Lipoxygenase Improves α-Galactosidase Efficacy in iPSC-Derived Cardiomyocytes from Fabry Patients. Int J Mol Sci 2018; 19:ijms19051480. [PMID: 29772700 PMCID: PMC5983630 DOI: 10.3390/ijms19051480] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2018] [Revised: 05/03/2018] [Accepted: 05/08/2018] [Indexed: 02/07/2023] Open
Abstract
(1) Background: A high incidence of intervening sequence (IVS)4+919 G>A mutation with later-onset cardiac phenotype have been reported in a majority of Taiwan Fabry cohorts. Some evidence indicated that conventional biomarkers failed to predict the long-term progression and therapeutic outcome; (2) Methods: In this study, we constructed an induced pluripotent stem cell (iPSC)-based platform from Fabry cardiomyopathy (FC) patients carrying IVS4+919 G>A mutation to screen for potential targets that may help the conventional treatment; (3) Results: The FC-patient-derived iPSC-differentiated cardiomyocytes (FC-iPSC-CMs) carried an expected IVS4+919 G>A genetic mutation and recapitulated several FC characteristics, including low α-galactosidase A enzyme activity and cellular hypertrophy. The proteomic analysis revealed that arachidonate 12/15-lipoxygenase (Alox12/15) was the most highly upregulated marker in FC-iPSC-CMs, and the metabolites of Alox12/15, 12(S)- and 15(S)-hydroxyeicosatetraenoic acid (HETE), were also elevated in the culture media. Late administration of Alox12/15 pharmacological inhibitor LOXBlock-1 combined with α-galactosidase, but not α-galactosidase alone, effectively reduced cardiomyocyte hypertrophy, the secretion of 12(S)- and 15(S)-HETE and the upregulation of fibrotic markers at the late phase of FC; (4) Conclusions: Our study demonstrates that cardiac Alox12/15 and circulating 12(S)-HETE/15(S)-HETE are involved in the pathogenesis of FC with IVS4+919 G>A mutation.
Collapse
Affiliation(s)
- Yueh Chien
- Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan.
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
| | - Shih-Jie Chou
- Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan.
| | - Yuh-Lih Chang
- Institute of Pharmacology, School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan.
- Department of Pharmacology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
| | - Hsin-Bang Leu
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan.
- Heath Care and Management Center, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
| | - Yi-Ping Yang
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
| | - Ping-Hsing Tsai
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan.
| | - Ying-Hsiu Lai
- Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
| | - Kuan-Hsuan Chen
- Department of Pharmacology, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan.
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, Taichung 40447, Taiwan.
| | - Shih-Hsien Sung
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan.
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
| | - Wen-Chung Yu
- Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei 11217, Taiwan.
- Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
| |
Collapse
|
49
|
Chien Y, Chien CS, Chiang HC, Huang WL, Chou SJ, Chang WC, Chang YL, Leu HB, Chen KH, Wang KL, Lai YH, Liu YY, Lu KH, Li HY, Sung YJ, Jong YJ, Chen YJ, Chen CH, Yu WC. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation. Oncotarget 2018; 7:87161-87179. [PMID: 27888626 PMCID: PMC5349979 DOI: 10.18632/oncotarget.13552] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2016] [Accepted: 11/07/2016] [Indexed: 12/19/2022] Open
Abstract
RATIONALE A high incidence of GLA IVS4+919 G>A mutation in patients with Fabry disease of the later-onset cardiac phenotype, has been reported in Taiwan. However, suitable biomarkers or potential therapeutic surrogates for Fabry cardiomyopathy (FC) in such patients under enzyme replacement treatment (ERT) remain unknown. OBJECTIVE Using FC patients carrying IVS4+919 G>A mutation, we constructed an induced pluripotent stem cell (iPSC)-based disease model to investigate the pathogenetic biomarkers and potential therapeutic targets in ERT-treated FC. RESULTS AND METHODS The iPSC-differentiated cardiomyocytes derived from FC-patients (FC-iPSC-CMs) carried IVS4+919 G>A mutation recapitulating FC characteristics, including low α-galactosidase A enzyme activity, cellular hypertrophy, and massive globotriaosylceramide accumulation. Microarray analysis revealed that interleukin-18 (IL-18), a pleiotropic cytokine involved in various myocardial diseases, was the most highly upregulated marker in FC-iPSC-CMs. Meanwhile, IL-18 levels were found to be significantly elevated in the culture media of FC-iPSC-CMs and patients' sera. Notably, the serum IL-18 levels were highly paralleled with the progression of left ventricular hypertrophy in Fabry patients receiving ERT. Finally, using FC-iPSC-CMs as in vitro FC model, neutralization of IL-18 with specific antibodies combined with ERT synergistically reduced the secretion of IL-18 and the progression of cardiomyocyte hypertrophy in FC-iPSC-CMs. CONCLUSION Our data demonstrated that cardiac IL-18 and circulating IL-18 are involved in the pathogenesis of FC and LVH. IL-18 may be a novel marker for evaluating ERT efficacy, and targeting IL-18 might be a potential adjunctive therapy combined with ERT for the treatment of advanced cardiomyopathy in FC patients with IVS4+919 G>A mutation.
Collapse
Affiliation(s)
- Yueh Chien
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Pharmacology, Taipei, Taiwan
| | - Chian-Shiu Chien
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Pharmacology, Taipei, Taiwan
| | - Huai-Chih Chiang
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Pharmacology, Taipei, Taiwan
| | - Wei-Lin Huang
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Anatomy and Cell Biology, Taipei, Taiwan
| | - Shih-Jie Chou
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Pharmacology, Taipei, Taiwan
| | - Wei-Chao Chang
- Graduate Institute of Cancer Biology and Center for Molecular Medicine, China Medical University and Department of Biotechnology, Asia University, Taichung, Taiwan
| | - Yuh-Lih Chang
- Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Pharmacology, Taipei, Taiwan
| | - Hsin-Bang Leu
- Division of Cardiology & Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Clinical Medicine, Taipei, Taiwan
| | - Kuan-Hsuan Chen
- Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Clinical Medicine, Taipei, Taiwan
| | - Kang-Ling Wang
- Division of Cardiology & Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Clinical Medicine, Taipei, Taiwan
| | | | - Yung-Yang Liu
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Clinical Medicine, Taipei, Taiwan
| | - Kai-Hsi Lu
- Department of Medical Research, Cheng-Hsin Hospital, Taipei, Taiwan
| | - Hsin-Yang Li
- Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.,Institute of Anatomy and Cell Biology, Taipei, Taiwan
| | - Yen-Jen Sung
- Institute of Anatomy and Cell Biology, Taipei, Taiwan
| | - Yuh-Jyh Jong
- College of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan
| | - Yann-Jang Chen
- Department of Life Sciences and Institute of Genome Sciences, Taipei, Taiwan
| | - Chung-Hsuan Chen
- Genomics Research Center, Academia Sinica, Taipei, Taiwan.,Department of Chemistry, National Taiwan University, Taipei, Taiwan
| | - Wen-Chung Yu
- Division of Cardiology & Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.,Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan
| |
Collapse
|
50
|
Fan CC, Cheng WC, Huang YC, Sher YP, Liou NJ, Chien YC, Lin PS, Lin PS, Chen CH, Chang WC. Publisher Correction: EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma. Sci Rep 2018; 8:1456. [PMID: 29348465 PMCID: PMC5773677 DOI: 10.1038/s41598-018-19645-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- Chi-Chen Fan
- Department of Superintendent Office, Mackay Memorial Hospital, Taipei, Taiwan.,Department of Medical Laboratory Science and Biotechnology, Yuanpei University, Hsinchu, Taiwan
| | - Wei-Chung Cheng
- Research Center for Tumor Medical Science, China Medical University, Taichung, Taiwan.,Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
| | - Yu-Chuen Huang
- School of Chinese Medicine, China Medical University, Taichung, Taiwan.,Genetics Center, Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
| | - Yuh-Pyng Sher
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.,Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
| | - Nia-Jhen Liou
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
| | - Yu-Chuan Chien
- Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
| | - Pei-Shan Lin
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
| | - Pei-Syuan Lin
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan
| | - Chung-Hsuan Chen
- Genomics Research Center, Academia Sinica, Taipei, Taiwan.,Institute of Biochemistry & Molecular Biology, National Yang-Ming University, Taipei, Taiwan.,Department of Chemistry, National Taiwan University, Taipei, Taiwan.,Institute of Atomic & Molecular Sciences, Academia Sinica, Taipei, Taiwan
| | - Wei-Chao Chang
- Center for Molecular Medicine, China Medical University Hospital, Taichung, Taiwan.
| |
Collapse
|